{"gene":"PPP1R1B","run_date":"2026-06-10T06:43:35","timeline":{"discoveries":[{"year":1984,"finding":"Phosphorylated DARPP-32 is a potent inhibitor of protein phosphatase-1 (PP-1) at nanomolar concentrations; inhibitory activity requires the phosphorylated (not dephosphorylated) form of the protein.","method":"In vitro phosphatase inhibition assay with purified DARPP-32 and PP-1","journal":"Nature","confidence":"High","confidence_rationale":"Tier 1 / Strong — direct in vitro enzymatic assay with purified components, foundational result replicated across many subsequent studies","pmids":["6087160"],"is_preprint":false},{"year":1984,"finding":"DARPP-32 is phosphorylated on a single threonine residue (Thr34) by both cAMP-dependent protein kinase (PKA) and cGMP-dependent protein kinase (PKG) in vitro, with kinetic parameters compatible with a physiological role for both kinases.","method":"In vitro kinase assay with purified PKA and PKG; two-dimensional phosphopeptide mapping; stoichiometry determination","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — reconstituted in vitro with purified components, phosphopeptide mapping, replicated in multiple papers","pmids":["6501303"],"is_preprint":false},{"year":1984,"finding":"DARPP-32 is phosphorylated in intact striatal cells by dopamine and by 8-bromo-cAMP, and in cell-free preparations by cAMP-dependent protein kinase, establishing a dopamine→cAMP→PKA→DARPP-32 signaling axis in dopaminoceptive neurons.","method":"Intact cell radiolabeling with [32P]; cell-free kinase assay","journal":"The Journal of neuroscience","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — both cell-free and intact-cell phosphorylation demonstrated, replicated across multiple labs","pmids":["6319627"],"is_preprint":false},{"year":1984,"finding":"DARPP-32 is an elongated monomeric protein of 202 residues with a calculated mass of ~22.6 kDa (anomalously high apparent MW on SDS-PAGE); it is highly hydrophilic with a high proline/glutamate content and a stretch of 16 consecutive acidic residues.","method":"Protein purification (435-fold), SDS-PAGE, hydrodynamic measurements (Stokes radius, sedimentation coefficient), amino acid composition","journal":"The Journal of neuroscience","confidence":"High","confidence_rationale":"Tier 1 / Strong — biochemical characterization of purified protein, sequence confirmed in follow-up study","pmids":["6319628"],"is_preprint":false},{"year":1986,"finding":"The complete amino acid sequence of bovine DARPP-32 was determined; the phosphorylation site for PKA is Thr34; the NH2-terminal region of DARPP-32 shares significant sequence identity with protein phosphatase inhibitor-1, suggesting a common structural basis for PP-1 inhibitory activity.","method":"Protein sequencing by automated Edman degradation of overlapping peptides from multiple enzymatic/chemical cleavages; sequence comparison","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — full primary structure determination by direct protein sequencing","pmids":["3511054"],"is_preprint":false},{"year":1989,"finding":"Casein kinase II (CK2) phosphorylates DARPP-32 in vitro at Ser45 and Ser102 (main site in intact cells is Ser102); phosphorylation by CK2 does not directly affect PP-1 inhibitory potency but facilitates subsequent phosphorylation of Thr34 by PKA (~2.2-fold increase in Vmax).","method":"In vitro kinase assay with purified CK2; phosphopeptide sequencing; manual Edman degradation; [32P]-labeling of intact caudate-putamen slices; kinetic analysis with synthetic peptides","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro reconstitution with site identification, intact-cell confirmation, and functional consequence measured","pmids":["2557337"],"is_preprint":false},{"year":1999,"finding":"Cyclin-dependent kinase 5 (Cdk5) phosphorylates DARPP-32 at Thr75 in vitro and in intact brain cells, converting DARPP-32 into an inhibitor of PKA by a competitive mechanism; this is distinct from the PP-1 inhibitory function conferred by Thr34 phosphorylation.","method":"In vitro kinase assay; intact brain cell [32P] labeling; Cdk5-specific inhibitor treatment; Cdk5 mutant mice; electrophysiological measurement of voltage-gated Ca2+ currents","journal":"Nature","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro reconstitution plus intact-cell validation plus genetic (mutant mouse) confirmation, replicated","pmids":["10604473"],"is_preprint":false},{"year":1997,"finding":"The NH2-terminal motif RKKIQF (residues 6–11) of DARPP-32 is required for PP-1 inhibition; Phe11 and Ile9 play critical roles. Peptides containing this motif antagonize inhibition of PP-1 by phospho-DARPP-32 and compete with PP-1 targeting/binding proteins, suggesting two-site interaction of phospho-DARPP-32 with PP-1 (active-site interaction via phospho-Thr34, and remote-site interaction via RKKIQF motif).","method":"Synthetic peptide competition assays; mutagenesis of DARPP-32; in vitro PP-1 inhibition assays","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro reconstitution with systematic mutagenesis and peptide competition, single lab but multiple orthogonal approaches","pmids":["9108011"],"is_preprint":false},{"year":1999,"finding":"Detailed mutagenesis of phospho-DARPP-32 identified Phe11, Ile9 (critical), Lys7 (lesser), Pro33, Pro35, and phospho-Thr34 as key residues for PP-1 inhibition; the spacing between residues 7–11 and phospho-Thr34 is also important. The KKIQF motif in DARPP-32 and IKGI in inhibitor-2 represent distinct NH2-terminal motifs critical for PP-1 inhibition.","method":"Site-directed mutagenesis; in vitro PP-1 inhibition assays (IC50 measurements); peptide competition","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — systematic mutagenesis with quantitative enzyme inhibition measurements","pmids":["10075680"],"is_preprint":false},{"year":1997,"finding":"Dopamine exerts bidirectional control of DARPP-32 phosphorylation: D1 receptor activation increases Thr34 phosphorylation (via PKA), while D2 receptor activation decreases Thr34 phosphorylation via a calcium-dependent calcineurin pathway (blocked by cyclosporin A and Ca2+-free/EGTA medium).","method":"Mouse striatal slice preparation; [32P] phosphorylation assay; pharmacological D1/D2 agonist/antagonist treatment; calcineurin inhibitor (cyclosporin A); Ca2+-free medium","journal":"The Journal of neuroscience","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple pharmacological tools in intact tissue, replicated across subsequent studies","pmids":["9334390"],"is_preprint":false},{"year":1999,"finding":"Calcineurin (PP2B) is the primary phosphatase responsible for dephosphorylating Thr34-phospho-DARPP-32 in neostriatal neurons, acting synergistically with PP2A (not PP-1); cyclosporin A (calcineurin inhibitor) produced a ~17-fold increase in phospho-DARPP-32 in striatal slices.","method":"Mouse neostriatal slice phosphorylation assay; pharmacological inhibitors (cyclosporin A, okadaic acid, calyculin A); Ca2+-free/EGTA medium","journal":"Journal of neurochemistry","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple selective inhibitors used in intact tissue, replicated in subsequent studies","pmids":["10217279"],"is_preprint":false},{"year":1998,"finding":"DARPP-32 knockout mice show profound deficits in molecular, electrophysiological, and behavioral responses to dopamine, drugs of abuse, and antipsychotic medication, establishing DARPP-32 as central to the efficacy of dopaminergic neurotransmission in vivo.","method":"Targeted gene disruption (knockout mouse); behavioral assays; electrophysiology; biochemical assays","journal":"Science","confidence":"High","confidence_rationale":"Tier 2 / Strong — clean genetic KO with multiple defined phenotypic readouts across labs","pmids":["9694658"],"is_preprint":false},{"year":2000,"finding":"D1 dopamine receptor stimulation reduces GABA-evoked currents in neostriatal medium spiny neurons through a PKA/DARPP-32/PP1 signaling cascade targeting GABA(A) receptor beta1/beta3 subunits; phosphorylation of beta1/beta3 subunits was attenuated in DARPP-32 mutant neurons.","method":"Whole-cell voltage-clamp recordings; immunoprecipitation of radiolabeled proteins; DARPP-32 knockout mice; single-cell RT-PCR","journal":"Journal of neurophysiology","confidence":"High","confidence_rationale":"Tier 2 / Strong — electrophysiology combined with biochemical IP and genetic KO, multiple methods","pmids":["10805695"],"is_preprint":false},{"year":2000,"finding":"DARPP-32 is required for progesterone-facilitated sexual receptivity in female rats and mice; progesterone increases hypothalamic cAMP levels and PKA activity, leading to Thr34-DARPP-32 phosphorylation; DARPP-32 is an obligate intermediate in progestin receptor-regulated sexual behavior.","method":"Antisense oligonucleotides to DARPP-32 in rats; DARPP-32 null mutant mice; behavioral assays; cAMP and PKA activity measurements; phospho-DARPP-32 immunoblot","journal":"Science","confidence":"High","confidence_rationale":"Tier 2 / Strong — antisense knockdown in rats corroborated by genetic KO in mice with defined behavioral phenotype","pmids":["10669419"],"is_preprint":false},{"year":2002,"finding":"DARPP-32 mediates the stimulant action of caffeine (via adenosine A2A receptor blockade) by increasing Thr75 phosphorylation; this occurs through inhibition of PP2A-catalyzed dephosphorylation of Thr75 rather than through stimulation of Cdk5.","method":"DARPP-32 knockout mice; locomotor activity assays; phospho-specific immunoblot of striatal tissue; pharmacological A2A antagonist/agonist treatment","journal":"Nature","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic KO with defined behavioral and biochemical phenotype, mechanism of Thr75 regulation dissected pharmacologically","pmids":["12181566"],"is_preprint":false},{"year":2002,"finding":"Fluoxetine regulates DARPP-32 phosphorylation at multiple sites (increases Thr34 and Ser137, decreases Thr75) in prefrontal cortex, hippocampus, and striatum; DARPP-32 mediates fluoxetine-induced phosphorylation of AMPA receptor GluR1 at Ser845 and the antidepressant behavioral response, as shown by attenuation in DARPP-32 knockout mice.","method":"In vivo drug administration; DARPP-32 knockout mice; phospho-specific immunoblots; animal test of antidepressant efficacy","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic KO with biochemical and behavioral phenotypes, multiple phosphorylation sites examined","pmids":["11880651"],"is_preprint":false},{"year":2002,"finding":"Prior D1 receptor activation and consequent DARPP-32 phosphorylation (with subsequent NR1-NMDA receptor phosphorylation) strongly reduces ethanol inhibition of NMDA responses in nucleus accumbens; this regulation was absent in DARPP-32 knockout mice.","method":"Rat/mouse nucleus accumbens slice electrophysiology; DARPP-32 knockout mice; pharmacological D1 receptor activation","journal":"Nature neuroscience","confidence":"High","confidence_rationale":"Tier 2 / Strong — electrophysiology in intact tissue plus genetic KO confirmation","pmids":["12068305"],"is_preprint":false},{"year":2005,"finding":"Glutamate regulates DARPP-32 phosphorylation at Thr34 and Thr75 through at least five distinct signaling cascades with different time dependencies: (1) NMDA/AMPA/mGluR5→nNOS/NO/cGMP/PKG→Thr34 increase; (2) NMDA/AMPA→Ca2+/PP2B→Thr34 decrease; (3) mGluR5/PLC/ERK→Thr34 rephosphorylation; (4) NMDA/AMPA→Ca2+/PP2A→Thr75 decrease; (5) mGluR1/PLC→Thr75 increase.","method":"Mouse neostriatal slice phosphorylation assay; selective receptor antagonists; phospho-specific immunoblots; NOS/NO pathway inhibitors","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 / Moderate — systematic pharmacological dissection of multiple signaling arms in intact tissue, single lab with multiple orthogonal inhibitors","pmids":["15657149"],"is_preprint":false},{"year":2007,"finding":"The PR72/B'' regulatory subunit of PP2A mediates Ca2+-dependent dephosphorylation of DARPP-32 at Thr75; PR72 contains two EF-hand Ca2+-binding sites and EF-hand 1 is necessary for Ca2+-dependent regulation of PP2A activity both in vitro and in vivo; this PP2A/PR72 complex is required for glutamate (AMPA/NMDA receptor)-induced Thr75 dephosphorylation.","method":"Overexpression and RNAi knockdown of PR72; in vitro PP2A assay; mutagenesis of EF-hand Ca2+-binding sites; striatal slice phosphorylation assay; glutamate receptor pharmacology","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — mutagenesis of regulatory domain combined with RNAi and in vitro assay, single lab with multiple orthogonal methods","pmids":["17535922"],"is_preprint":false},{"year":2006,"finding":"Phosphorylation of DARPP-32 at Thr34 is required for cocaine-induced conditioned place preference, acute locomotor response, and immediate early gene induction (c-fos, arc) in striatum; Thr75 phosphorylation is required for locomotor sensitization to repeated cocaine but not for acute locomotor response or conditioned place preference.","method":"Knock-in mice with T34A or T75A point mutations in DARPP-32; behavioral assays (CPP, locomotor activity, sensitization); striatal gene expression analysis","journal":"Neuropsychopharmacology","confidence":"High","confidence_rationale":"Tier 2 / Strong — site-specific knock-in mutations with multiple behavioral and biochemical readouts","pmids":["16123776"],"is_preprint":false},{"year":2007,"finding":"Sensitized cAMP/PKA/DARPP-32 signaling in L-DOPA-induced dyskinesia leads to sequential phosphorylation of ERK1/2, MSK-1, and histone H3 in striatal medium spiny neurons; genetic inactivation of DARPP-32 reduces dyskinesia, and pharmacological inhibition of MEK counteracts LID induction.","method":"DARPP-32 knockout mice; L-DOPA-treated mouse model of dyskinesia; phospho-specific immunoblots; MEK inhibitor (SL327) treatment; c-Fos expression analysis","journal":"The Journal of neuroscience","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic KO plus pharmacological intervention with defined biochemical cascade and behavioral phenotype","pmids":["17596448"],"is_preprint":false},{"year":2008,"finding":"Cocaine (psychostimulant) and haloperidol (antipsychotic) exert opposing, cell-type-specific effects on DARPP-32 Thr34 phosphorylation: cocaine preferentially increases phospho-Thr34 in striatonigral (D1) neurons, while haloperidol preferentially increases it in striatopallidal (D2) neurons.","method":"BAC transgenic mice enabling cell-type-selective DARPP-32 phosphorylation analysis; phospho-specific immunoblots from FACS-sorted neuronal populations","journal":"Nature neuroscience","confidence":"High","confidence_rationale":"Tier 2 / Strong — novel cell-type-selective genetic tool combined with biochemical readout, multiple drugs tested","pmids":["18622401"],"is_preprint":false},{"year":2009,"finding":"Wnt-5a triggers cAMP elevation and Thr34-DARPP-32 phosphorylation in breast cancer cells via Frizzled-3/Gαs/PKA signaling; phospho-Thr34-DARPP-32 interacts with PP1, potentiates CREB phosphorylation, reduces Cdc42 activity and filopodia formation, and thereby inhibits MCF-7 breast cancer cell migration.","method":"Recombinant Wnt-5a treatment; siRNA knockdown of Frizzled-3, Gαs, DARPP-32; PKA inhibitors; dominant-negative CREB expression; cAMP imaging; Cdc42 activity assay; phalloidin staining; migration assay","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal approaches (siRNA, dominant-negative, imaging, activity assays) in single lab","pmids":["19651774"],"is_preprint":false},{"year":2006,"finding":"DARPP-32 expression in non-transformed mammary cells inhibits cell migration downstream of the collagen receptor DDR1; phosphorylation of Thr34 (but not Thr75) is necessary for this antimigratory effect; co-expression of DDR1 and DARPP-32 is required for migration inhibition.","method":"Transfection of MCF7 and MDA-MB-231 cells with DARPP-32 mutants; cell migration assay; immunoblot analysis","journal":"Experimental cell research","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — site-specific mutagenesis with functional readout, single lab, single method for migration","pmids":["17027969"],"is_preprint":false},{"year":2014,"finding":"Bcl-2 binds DARPP-32 and docks it with calcineurin (CaN) in a complex on the InsP3R, creating a negative feedback loop: PKA phosphorylates InsP3R and DARPP-32; phospho-DARPP-32 inhibits PP1, enhancing InsP3R phosphorylation and Ca2+ release; elevated Ca2+ activates CaN, which dephosphorylates DARPP-32 to dampen further Ca2+ release. Knockdown of Bcl-2 or DARPP-32 disrupts this feedback and increases apoptosis.","method":"Co-immunoprecipitation; RNAi knockdown of Bcl-2 and DARPP-32; Ca2+ measurement; apoptosis assay; T-cell activation experiments","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reciprocal Co-IP establishing complex, functional consequences via RNAi, single lab","pmids":["24395794"],"is_preprint":false},{"year":2015,"finding":"DARPP-32 interacts physically with adducins (cytoskeletal actin-capping proteins) via the adducin MARCKS domain; this interaction is modulated by DARPP-32 Ser97 phosphorylation. Phospho-Thr75-DARPP-32 facilitates β-adducin Ser713 phosphorylation through inhibition of a PKA/PP2A cascade. This pathway is implicated in environmental enrichment-induced changes in nucleus accumbens dendritic spines and cocaine locomotor responses.","method":"Co-immunoprecipitation; DARPP-32 T75A knock-in mice; phospho-specific immunoblots; dendritic spine analysis; cocaine locomotor assay","journal":"Nature communications","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reciprocal Co-IP plus knock-in mouse with defined structural and behavioral phenotype, single lab","pmids":["26639316"],"is_preprint":false},{"year":2011,"finding":"DARPP-32 colocalizes with EGFR on the cell membrane in a complex with EGFR and ERBB3; overexpression of DARPP-32 stabilizes EGFR, increases EGFR-ERBB3 interaction and phosphorylation, activates AKT (Ser473), and confers resistance to gefitinib in gastric cancer cells.","method":"Co-immunoprecipitation; immunofluorescence colocalization; clonogenic survival assay; Annexin-V apoptosis assay; shRNA knockdown; mouse xenograft model","journal":"Gastroenterology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP establishing complex plus functional knockdown/overexpression with in vivo validation, single lab","pmids":["21741919"],"is_preprint":false},{"year":2013,"finding":"DARPP-32 physically interacts with IGF1R and promotes its phosphorylation (Y1135), leading to activation of downstream SRC and STAT3 (Y705 phosphorylation, nuclear localization, transcription activation); in DARPP-32 knockout/TFF1 knockout double-mutant mice, IGF1R and STAT3 phosphorylation is absent, and gastric neoplasia development is delayed.","method":"Proximity ligation assay; co-immunoprecipitation; 3D gastric organoids; double-knockout mouse model (TFF1 KO × DARPP-32 KO); immunohistochemistry of human gastric cancer tissue arrays","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — proximity ligation + Co-IP establishing complex, genetic in vivo validation, single lab","pmids":["31235784"],"is_preprint":false},{"year":2015,"finding":"DARPP-32 regulates ANGPT2-mediated tumor angiogenesis through a STAT3-dependent (not NF-κB-dependent) mechanism; this effect is independent of Thr34-mediated PP1 inhibition, as T34A mutant and truncated t-DARPP produce similar ANGPT2 induction; DARPP-32 activates STAT3 phosphorylation and nuclear localization.","method":"DARPP-32 overexpression/knockdown; quantitative RT-PCR; immunoblot; luciferase reporter; HUVEC tube formation assay; STAT3 inhibitor/siRNA; in vivo xenograft tumor model; immunohistochemistry of human gastric cancer tissues","journal":"Gut","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple cell-based assays plus in vivo xenograft with STAT3 mechanistic dissection, single lab","pmids":["25779598"],"is_preprint":false},{"year":2015,"finding":"DARPP-32 forms a protein complex with SRp20 splicing factor (co-immunoprecipitation), regulates SRp20 protein stability (via alternative splicing inhibitor digitoxin experiments), and thereby controls CD44E (CD44 V8-V10) splice variant expression to promote gastric cancer cell proliferation in vitro and tumor growth in vivo.","method":"siRNA/shRNA knockdown; splicing luciferase reporter; co-immunoprecipitation; immunoprecipitation with digitoxin; tumor xenograft model; SRp20 reconstitution rescue experiment; human gastric cancer tissue analysis","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP establishing complex, functional rescue experiment with SRp20 reconstitution, in vivo validation, single lab","pmids":["26119931"],"is_preprint":false},{"year":2012,"finding":"DARPP-32 forms a protein complex with CXCR4 (co-immunoprecipitation and immunofluorescence); DARPP-32 prolongs CXCR4 protein half-life, reduces CXCL12-induced CXCR4 ubiquitination, and promotes gastric cancer cell invasion through CXCR4-dependent activation of the MT1-MMP/MMP-2 pathway.","method":"Reciprocal co-immunoprecipitation; immunofluorescence; CXCR4 antagonist (AMD3100) and siRNA; MMP-2 activity assay; Matrigel invasion assay; impedance-based invasion assay; DARPP-32 overexpression/knockdown","journal":"Molecular cancer research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reciprocal Co-IP establishing complex, functional validation with antagonist and siRNA, single lab","pmids":["23160836"],"is_preprint":false},{"year":2018,"finding":"DARPP-32 physically interacts with IKKα (inhibitory kappa B kinase-α), and this interaction promotes NSCLC cell migration through non-canonical NF-κB2 signaling; abrogation of DARPP-32 expression reduces tumor growth in orthotopic mouse models.","method":"Co-immunoprecipitation; shRNA knockdown; orthotopic mouse tumor model; NF-κB2 signaling analysis; patient tissue immunohistochemistry","journal":"Communications biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP establishing novel interaction, in vivo orthotopic model, single lab","pmids":["29782621"],"is_preprint":false},{"year":2016,"finding":"H. pylori infection induces DARPP-32 expression through NF-κB transcriptional activation: ChIP and deletion-based luciferase reporter identified the DARPP-32 promoter region −996 to −1008 bp (containing NF-κB-binding sites) as the key regulatory element; DARPP-32 induction counteracts H. pylori-induced cell death through AKT activation.","method":"Luciferase reporter assays with DARPP-32 promoter deletions; ChIP assay; H. pylori infection of gastric cancer cells and mice; ATP-Glo and clonogenic survival assays; immunohistochemistry of gastric cancer tissues","journal":"Gut","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP confirming NF-κB binding at defined promoter region plus functional cell survival assays, single lab","pmids":["27590997"],"is_preprint":false},{"year":2020,"finding":"Loss of HIF1A in pancreatic cancer cells increases PPP1R1B expression; elevated PPP1R1B promotes p53 degradation by stabilizing phosphorylation of MDM2 at Ser166; knockdown of PPP1R1B reduces the ability of pancreatic cancer cells to form lung metastases in mice.","method":"KPC mouse models with pancreas-specific HIF1A deletion; shRNA knockdown of PPP1R1B; immunoblot; in vivo lung metastasis assay; liquid chromatography-mass spectrometry","journal":"Gastroenterology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo genetic model with mechanistic biochemical follow-up, single lab","pmids":["32768595"],"is_preprint":false},{"year":2005,"finding":"DARPP-32 and its truncated isoform t-DARPP exert antiapoptotic effects in gastrointestinal cancer cells through a p53-independent mechanism involving preservation of mitochondrial transmembrane potential and increased Bcl-2 levels; antiapoptotic activity required intact phosphorylation sites.","method":"Overexpression of DARPP-32 and t-DARPP with phosphorylation site mutations; TUNEL and Annexin-V apoptosis assays; mitochondrial membrane potential assay; siRNA knockdown; luciferase reporters for p53/p21","journal":"Cancer research","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — mutagenesis with functional apoptosis assays, phosphorylation site dependency shown, single lab","pmids":["16061638"],"is_preprint":false},{"year":2002,"finding":"The truncated isoform t-DARPP lacks the Thr34 phosphorylation site (PP-1 inhibitory site) but retains the Thr75 site (PKA inhibitory site); both full-length DARPP-32 and t-DARPP are overexpressed in gastric cancers.","method":"cDNA cloning; RT-PCR; Western blotting; tumor tissue array analysis","journal":"Cancer research","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — molecular characterization of novel isoform with structural inference, replicated in multiple subsequent studies","pmids":["12124342"],"is_preprint":false},{"year":2009,"finding":"t-DARPP overexpression in breast cancer cells is sufficient to confer trastuzumab resistance and sustain Akt phosphorylation; the Thr75 residue in t-DARPP is required for both Akt activation and trastuzumab resistance; full-length DARPP-32 co-expression reverses these effects. t-DARPP also increases CREB binding activity.","method":"Gene silencing (RNAi); transfection of t-DARPP and DARPP-32 cDNAs; T75 mutagenesis; trastuzumab resistance assay; Akt phosphorylation immunoblot; CREB DNA binding assay","journal":"Breast cancer research and treatment / PloS one","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — site-specific mutagenesis with functional drug resistance readout, corroborated by two independent labs (PMID 19301121 and 19593441)","pmids":["19301121","19593441"],"is_preprint":false},{"year":1990,"finding":"Casein kinase II activity identified in caudate-putamen cytosol phosphorylates DARPP-32 on the same seryl residue as purified CK2; CK2-like immunoreactivity colocalizes with DARPP-32 in medium-sized striatonigral neurons; ~45% of total CK2 activity is cytosolic in rat caudate-putamen.","method":"Biochemical kinase characterization; excitotoxic lesions (kainic acid); immunocytochemistry; subcellular fractionation","journal":"Journal of neurochemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — biochemical identity of endogenous kinase established with multiple criteria plus cellular colocalization","pmids":["2145398"],"is_preprint":false},{"year":1994,"finding":"GABA increases Thr34-phosphorylation of DARPP-32 in striatal and substantia nigra slices through GABA-A receptors (blocked by bicuculline); the mechanism is consistent with GABA reducing calcineurin-mediated dephosphorylation rather than directly activating PKA (cAMP was not elevated).","method":"Striatal and substantia nigra slice [32P] phosphorylation assay; GABA-A/B receptor antagonists; pharmacological synergy with forskolin/L-DOPA","journal":"Journal of neurochemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — pharmacological dissection in intact tissue, mechanistic inference indirect, single lab","pmids":["7931332"],"is_preprint":false},{"year":1999,"finding":"Mu-opioid receptors (via DAMGO) specifically inhibit D1-stimulated DARPP-32 phosphorylation in striatonigral neurons, while delta-opioid receptors (via DPDPE) specifically inhibit A2A-stimulated DARPP-32 phosphorylation in striatopallidal neurons; kappa-opioid receptors had no effect.","method":"Rat striatal slice phosphorylation assay with selective opioid receptor agonists; D1 and A2A receptor pharmacology","journal":"The European journal of neuroscience","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — cell-type-specific pharmacological dissection in intact tissue, single lab","pmids":["10336688"],"is_preprint":false},{"year":2009,"finding":"DARPP-32 co-immunoprecipitates with all five dopamine receptor subtypes (D1–D5) from rat brain cortex and striatum, suggesting direct or indirect physical association in neurons.","method":"Co-immunoprecipitation from brain tissue lysates; western blot; immunohistochemistry","journal":"Neuroscience research","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single Co-IP from tissue lysate without reciprocal pulldown or functional consequence, single lab","pmids":["19465068"],"is_preprint":false},{"year":1992,"finding":"In choroid plexus epithelial cells, DARPP-32 is phosphorylated in response to factors that increase cAMP (forskolin, isoproterenol, VIP) or cGMP (ANP) or activate other pathways (5-HT), but not by dopamine, indicating context-specific regulation of DARPP-32 by non-dopaminergic signals.","method":"Phosphorylation state-specific monoclonal antibody; intact choroid plexus cell phosphorylation assay; cAMP/cGMP measurements","journal":"The Journal of neuroscience","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — phosphorylation state-specific antibody with pharmacological characterization, novel context established, single lab","pmids":["1494946"],"is_preprint":false}],"current_model":"DARPP-32 (PPP1R1B) is a dual-function signaling hub in dopaminoceptive neurons: when phosphorylated at Thr34 by PKA (activated downstream of D1 receptors/cAMP), it becomes a potent nanomolar inhibitor of protein phosphatase-1; when phosphorylated at Thr75 by Cdk5, it instead inhibits PKA by a competitive mechanism. These two phosphorylation states are modulated by CK2 (Ser102/Ser45), CK1 (Ser137), and multiple phosphatases including calcineurin (dephosphorylates Thr34) and a PR72-containing PP2A complex (dephosphorylates Thr75 in a Ca2+-dependent manner), enabling DARPP-32 to integrate dopamine, glutamate, serotonin, adenosine, opioid, GABA, and other signals into graded control of PP1 and PKA activity. In cancer contexts, DARPP-32 forms physical complexes with EGFR/ERBB3, CXCR4, IGF1R, IKKα, SRp20, and Bcl-2, and activates AKT, STAT3, and NF-κB2 pathways to promote survival, invasion, angiogenesis, and drug resistance."},"narrative":{"mechanistic_narrative":"PPP1R1B (DARPP-32) is a phosphorylation-state-controlled signaling integrator in dopaminoceptive neurons that converts upstream neuromodulatory inputs into bidirectional control of protein phosphatase-1 (PP-1) and PKA activity [PMID:6087160, PMID:10604473]. When phosphorylated on Thr34 by PKA — the terminal step of a dopamine→cAMP→PKA cascade engaged downstream of D1 receptors — it becomes a nanomolar inhibitor of PP-1, an inhibition that requires both the phospho-Thr34 active-site contact and an N-terminal RKKIQF motif (Phe11, Ile9) for a two-site interaction with the phosphatase [PMID:6087160, PMID:6319627, PMID:9108011, PMID:10075680]. The N-terminal region shares sequence identity with phosphatase inhibitor-1, defining a common structural basis for PP-1 inhibition [PMID:3511054]. A distinct phosphorylation by Cdk5 at Thr75 instead converts DARPP-32 into a competitive inhibitor of PKA, so the protein operates as a reciprocal molecular switch between the two states [PMID:10604473]. These states are tuned by additional kinases and phosphatases — CK2 phosphorylates Ser45/Ser102 and accelerates PKA phosphorylation of Thr34 [PMID:2557337, PMID:2145398], calcineurin (PP2B) is the principal Thr34 phosphatase [PMID:9334390, PMID:10217279], and a Ca2+-sensing PR72/PP2A complex dephosphorylates Thr75 [PMID:17535922] — allowing DARPP-32 to integrate dopamine, glutamate, GABA, adenosine, opioid, and serotonergic signals into graded phosphatase/kinase control [PMID:9334390, PMID:12181566, PMID:15657149, PMID:7931332, PMID:10336688]. In vivo, DARPP-32 is essential for molecular, electrophysiological, and behavioral responses to dopamine and psychoactive drugs, acting through site-specific Thr34 and Thr75 phosphorylation to govern responses to cocaine, antidepressants, and L-DOPA-induced dyskinesia [PMID:9694658, PMID:11880651, PMID:16123776, PMID:17596448]. Beyond neurons, DARPP-32 and its truncated isoform t-DARPP function in epithelial cancers, where they physically partner with EGFR/ERBB3, IGF1R, CXCR4, and IKKα to activate AKT, STAT3, and NF-κB2 signaling and to promote survival, invasion, angiogenesis, and drug resistance [PMID:21741919, PMID:31235784, PMID:25779598, PMID:23160836, PMID:29782621, PMID:19301121, PMID:19593441].","teleology":[{"year":1984,"claim":"Established the core biochemical function: that a neuronal phosphoprotein acts as a phosphorylation-dependent inhibitor of PP-1, defining DARPP-32 as a signaling effector rather than a passive substrate.","evidence":"In vitro phosphatase inhibition assay with purified DARPP-32 and PP-1; biochemical purification and hydrodynamic characterization","pmids":["6087160","6319628"],"confidence":"High","gaps":["Did not define the responsible kinase or the phosphorylated residue","No structural model of the DARPP-32/PP-1 contact"]},{"year":1984,"claim":"Identified the activating kinase and signaling input, linking dopamine to DARPP-32 via a cAMP/PKA cascade and showing PKA (and PKG) phosphorylate a single threonine.","evidence":"In vitro PKA/PKG kinase assay with phosphopeptide mapping; intact striatal cell [32P] labeling with dopamine and 8-bromo-cAMP","pmids":["6501303","6319627"],"confidence":"High","gaps":["Exact residue identity not yet assigned at sequence level","Phosphatase responsible for reversal unknown"]},{"year":1986,"claim":"Resolved the molecular basis of inhibition by determining the full sequence, mapping the PKA site to Thr34, and revealing homology to inhibitor-1.","evidence":"Edman degradation of bovine DARPP-32 peptides; sequence comparison with inhibitor-1","pmids":["3511054"],"confidence":"High","gaps":["Did not define which N-terminal residues contact PP-1","Other phosphorylation sites and their kinases unknown"]},{"year":1989,"claim":"Showed multi-site regulation by identifying CK2 phosphorylation at Ser45/Ser102 that primes Thr34 phosphorylation, introducing hierarchical control of inhibitory potency.","evidence":"In vitro CK2 kinase assay with phosphopeptide sequencing; intact slice labeling; kinetic analysis; endogenous striatal CK2 characterization","pmids":["2557337","2145398"],"confidence":"High","gaps":["Physiological trigger of CK2 activity in neurons not defined","Functional impact of Ser45 vs Ser102 not separated in vivo"]},{"year":1997,"claim":"Defined the structural determinants of PP-1 inhibition, establishing a two-site mechanism requiring both phospho-Thr34 and an N-terminal RKKIQF motif.","evidence":"Synthetic peptide competition and DARPP-32 mutagenesis with in vitro PP-1 inhibition assays","pmids":["9108011","10075680"],"confidence":"High","gaps":["No co-crystal structure of the DARPP-32/PP-1 complex","Whether the two sites engage PP-1 simultaneously in cells untested"]},{"year":1997,"claim":"Demonstrated bidirectional dopaminergic control, with D1 increasing and D2 decreasing Thr34 phosphorylation via a Ca2+/calcineurin pathway, and identified calcineurin as the principal Thr34 phosphatase.","evidence":"Striatal slice [32P] assays with D1/D2 pharmacology, calcineurin inhibitors, and Ca2+-free media","pmids":["9334390","10217279"],"confidence":"High","gaps":["Spatial coupling of calcineurin to DARPP-32 not resolved","Contribution of PP2A versus calcineurin quantitatively uncertain"]},{"year":1999,"claim":"Revealed the second, opposing switch state: Cdk5 phosphorylation at Thr75 converts DARPP-32 into a competitive PKA inhibitor, making it a reciprocal kinase/phosphatase integrator.","evidence":"In vitro Cdk5 kinase assay, intact brain cell labeling, Cdk5 inhibitor and mutant mice, Ca2+ current electrophysiology","pmids":["10604473"],"confidence":"High","gaps":["Phosphatase reversing Thr75 not yet identified at this stage","Crosstalk dynamics between Thr34 and Thr75 states unresolved"]},{"year":1998,"claim":"Established physiological necessity in vivo by showing DARPP-32 knockout disrupts dopaminergic molecular, electrophysiological, and behavioral responses.","evidence":"Targeted knockout mouse with behavioral, electrophysiological, and biochemical readouts","pmids":["9694658"],"confidence":"High","gaps":["Did not separate Thr34 from Thr75 contributions","Cell-type-specific roles not resolved"]},{"year":2002,"claim":"Mapped DARPP-32 downstream effectors and broadened its signaling inputs, linking it to GABA(A), NMDA, AMPA-receptor regulation and to adenosine, serotonergic, and antidepressant pathways through site-specific phosphorylation.","evidence":"DARPP-32 knockout mice, slice electrophysiology, phospho-specific immunoblots, and pharmacology across striatal, accumbens, and cortical preparations","pmids":["10805695","12181566","11880651","12068305","15657149","7931332","10336688"],"confidence":"High","gaps":["Quantitative integration of competing inputs at single-neuron resolution incomplete","Direct substrate phosphorylation by PP-1/PKA versus indirect effects not always separated"]},{"year":2007,"claim":"Identified the Ca2+-sensing Thr75 phosphatase, showing a PR72/PP2A complex with functional EF-hands dephosphorylates Thr75 in response to glutamate-driven Ca2+.","evidence":"PR72 overexpression/RNAi, EF-hand mutagenesis, in vitro PP2A assay, and striatal slice phosphorylation with glutamate receptor pharmacology","pmids":["17535922"],"confidence":"High","gaps":["Stoichiometry and assembly of the PR72/PP2A/DARPP-32 module unresolved","Whether PR72 directly binds DARPP-32 not shown"]},{"year":2008,"claim":"Resolved cell-type-specific regulation, showing psychostimulants and antipsychotics drive Thr34 phosphorylation in opposite striatal neuron populations, and dissected site-specific behavioral roles.","evidence":"BAC transgenic and T34A/T75A knock-in mice with FACS-based phospho-analysis and behavioral assays","pmids":["18622401","16123776","17596448"],"confidence":"High","gaps":["Molecular basis of divergent D1 versus D2 neuron responses not fully defined","Link from H3/ERK cascade to specific transcriptional programs incomplete"]},{"year":2009,"claim":"Extended DARPP-32 function beyond neurons to epithelial and reproductive contexts, showing canonical Thr34/PP-1 signaling controls cell migration and sexual behavior.","evidence":"Wnt-5a/Frizzled-3 signaling with siRNA and Cdc42 assays in MCF-7 cells; DDR1-dependent migration with DARPP-32 mutants; antisense and knockout for progesterone-facilitated receptivity","pmids":["19651774","17027969","10669419"],"confidence":"Medium","gaps":["Antimigratory cancer findings rest largely on single-lab cell models","Generality across epithelial cell types not established"]},{"year":2014,"claim":"Placed DARPP-32 in a Ca2+/apoptosis feedback module, showing Bcl-2 docks DARPP-32 with calcineurin on the InsP3R to create a negative-feedback loop that limits apoptosis.","evidence":"Reciprocal co-immunoprecipitation, Bcl-2/DARPP-32 RNAi, Ca2+ and apoptosis assays","pmids":["24395794"],"confidence":"Medium","gaps":["Co-IP-based complex not validated structurally","Generality beyond the studied cell systems unclear"]},{"year":2018,"claim":"Defined oncogenic protein-complex partners through which DARPP-32/t-DARPP activate survival and invasion pathways, including EGFR/ERBB3, IGF1R, CXCR4, IKKα, SRp20, and downstream AKT/STAT3/NF-κB2 signaling.","evidence":"Co-immunoprecipitation, proximity ligation, shRNA/siRNA, organoids, knock-in/knockout and xenograft/orthotopic mouse models, and human tumor tissue analysis","pmids":["21741919","31235784","25779598","26119931","23160836","29782621","27590997","32768595","16061638","12124342","19301121","19593441"],"confidence":"Medium","gaps":["Most interactions established by Co-IP in single labs without structural mapping","Whether catalytic phosphatase-inhibitory activity is required for many cancer phenotypes is inconsistent across studies","t-DARPP versus full-length contributions not always separated"]},{"year":null,"claim":"How the competing Thr34 and Thr75 phosphorylation states, their kinases, and their phosphatases are spatially and temporally coordinated at the level of individual synapses or signaling complexes remains unresolved, as does the structural basis of the many cancer-associated receptor complexes.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No structural model of DARPP-32 bound to PP-1 or to cancer receptor partners","Quantitative model integrating all kinase/phosphatase inputs at single-cell resolution lacking"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[0,6,7,8]},{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[0,7]},{"term_id":"GO:0060089","term_label":"molecular transducer activity","supporting_discovery_ids":[2,6,9]}],"localization":[{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[37]},{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[26,30]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[2,6,9]},{"term_id":"R-HSA-112316","term_label":"Neuronal System","supporting_discovery_ids":[11,12,16]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[26,28,30,31]}],"complexes":[],"partners":["PPP1CA","CDK5","CSNK2A1","PPP3CA","EGFR","ERBB3","IGF1R","CXCR4"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q9UD71","full_name":"Protein phosphatase 1 regulatory subunit 1B","aliases":["DARPP-32","Dopamine- and cAMP-regulated neuronal phosphoprotein"],"length_aa":204,"mass_kda":23.0,"function":"Inhibitor of protein-phosphatase 1","subcellular_location":"Cytoplasm","url":"https://www.uniprot.org/uniprotkb/Q9UD71/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/PPP1R1B","classification":"Not Classified","n_dependent_lines":19,"n_total_lines":1208,"dependency_fraction":0.015728476821192054},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/PPP1R1B","total_profiled":1310},"omim":[{"mim_id":"611802","title":"MIGRATION AND INVASION ENHANCER 1; MIEN1","url":"https://www.omim.org/entry/611802"},{"mim_id":"611801","title":"POST-GPI ATTACHMENT TO PROTEINS 3; PGAP3","url":"https://www.omim.org/entry/611801"},{"mim_id":"611241","title":"GPRIN FAMILY, MEMBER 3; GPRIN3","url":"https://www.omim.org/entry/611241"},{"mim_id":"611221","title":"GASDERMIN B; GSDMB","url":"https://www.omim.org/entry/611221"},{"mim_id":"607468","title":"G PROTEIN-COUPLED RECEPTOR 88; GPR88","url":"https://www.omim.org/entry/607468"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Group enriched","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"brain","ntpm":1368.7},{"tissue":"choroid plexus","ntpm":1463.9}],"url":"https://www.proteinatlas.org/search/PPP1R1B"},"hgnc":{"alias_symbol":["DARPP-32","FLJ20940"],"prev_symbol":[]},"alphafold":{"accession":"Q9UD71","domains":[],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9UD71","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q9UD71-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q9UD71-F1-predicted_aligned_error_v6.png","plddt_mean":65.19},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=PPP1R1B","jax_strain_url":"https://www.jax.org/strain/search?query=PPP1R1B"},"sequence":{"accession":"Q9UD71","fasta_url":"https://rest.uniprot.org/uniprotkb/Q9UD71.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q9UD71/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9UD71"}},"corpus_meta":[{"pmid":"14744247","id":"PMC_14744247","title":"DARPP-32: an integrator of neurotransmission.","date":"2004","source":"Annual review of pharmacology and toxicology","url":"https://pubmed.ncbi.nlm.nih.gov/14744247","citation_count":564,"is_preprint":false},{"pmid":"6087160","id":"PMC_6087160","title":"DARPP-32, a dopamine-regulated neuronal phosphoprotein, is a potent inhibitor of protein phosphatase-1.","date":"1984","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/6087160","citation_count":543,"is_preprint":false},{"pmid":"6319625","id":"PMC_6319625","title":"DARPP-32, a dopamine- and adenosine 3':5'-monophosphate-regulated phosphoprotein enriched in dopamine-innervated brain regions. III. Immunocytochemical localization.","date":"1984","source":"The Journal of neuroscience : the official journal of the Society for Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/6319625","citation_count":538,"is_preprint":false},{"pmid":"10604473","id":"PMC_10604473","title":"Phosphorylation of DARPP-32 by Cdk5 modulates dopamine signalling in neurons.","date":"1999","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/10604473","citation_count":474,"is_preprint":false},{"pmid":"9694658","id":"PMC_9694658","title":"DARPP-32: regulator of the efficacy of dopaminergic neurotransmission.","date":"1998","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/9694658","citation_count":384,"is_preprint":false},{"pmid":"17596448","id":"PMC_17596448","title":"Critical involvement of cAMP/DARPP-32 and extracellular signal-regulated protein kinase signaling in L-DOPA-induced dyskinesia.","date":"2007","source":"The Journal of neuroscience : the official journal of the Society for Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/17596448","citation_count":351,"is_preprint":false},{"pmid":"9334390","id":"PMC_9334390","title":"Bidirectional regulation of DARPP-32 phosphorylation by dopamine.","date":"1997","source":"The Journal of neuroscience : the official journal of the Society for Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/9334390","citation_count":320,"is_preprint":false},{"pmid":"6319627","id":"PMC_6319627","title":"DARPP-32, a dopamine- and adenosine 3':5'-monophosphate-regulated phosphoprotein enriched in dopamine-innervated brain regions. I. Regional and cellular distribution in the rat brain.","date":"1984","source":"The Journal of neuroscience : the official journal of the Society for Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/6319627","citation_count":277,"is_preprint":false},{"pmid":"3711991","id":"PMC_3711991","title":"DARPP-32, a dopamine- and adenosine 3':5'-monophosphate-regulated phosphoprotein: regional, tissue, and phylogenetic distribution.","date":"1986","source":"The Journal of neuroscience : the official journal of the Society for Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/3711991","citation_count":216,"is_preprint":false},{"pmid":"18622401","id":"PMC_18622401","title":"Cell type-specific regulation of DARPP-32 phosphorylation by psychostimulant and antipsychotic drugs.","date":"2008","source":"Nature neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/18622401","citation_count":195,"is_preprint":false},{"pmid":"11880651","id":"PMC_11880651","title":"Involvement of striatal and extrastriatal DARPP-32 in biochemical and behavioral effects of fluoxetine (Prozac).","date":"2002","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/11880651","citation_count":187,"is_preprint":false},{"pmid":"6319628","id":"PMC_6319628","title":"DARPP-32, a dopamine- and adenosine 3':5'-monophosphate-regulated phosphoprotein enriched in dopamine-innervated brain regions. II. Purification and characterization of the phosphoprotein from bovine caudate nucleus.","date":"1984","source":"The Journal of neuroscience : the official journal of the Society for Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/6319628","citation_count":175,"is_preprint":false},{"pmid":"17290303","id":"PMC_17290303","title":"Genetic evidence implicating DARPP-32 in human frontostriatal structure, function, and cognition.","date":"2007","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/17290303","citation_count":164,"is_preprint":false},{"pmid":"2557337","id":"PMC_2557337","title":"Phosphorylation of DARPP-32, a dopamine- and cAMP-regulated phosphoprotein, by casein kinase II.","date":"1989","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/2557337","citation_count":144,"is_preprint":false},{"pmid":"12150646","id":"PMC_12150646","title":"Evidence for decreased DARPP-32 in the prefrontal cortex of patients with schizophrenia.","date":"2002","source":"Archives of general psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/12150646","citation_count":139,"is_preprint":false},{"pmid":"12181566","id":"PMC_12181566","title":"Involvement of DARPP-32 phosphorylation in the stimulant action of caffeine.","date":"2002","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/12181566","citation_count":134,"is_preprint":false},{"pmid":"17194217","id":"PMC_17194217","title":"DARPP-32 is a robust integrator of dopamine and glutamate signals.","date":"2006","source":"PLoS computational biology","url":"https://pubmed.ncbi.nlm.nih.gov/17194217","citation_count":130,"is_preprint":false},{"pmid":"16353915","id":"PMC_16353915","title":"DARPP-32 mediates the actions of multiple drugs of abuse.","date":"2005","source":"The AAPS journal","url":"https://pubmed.ncbi.nlm.nih.gov/16353915","citation_count":128,"is_preprint":false},{"pmid":"1494946","id":"PMC_1494946","title":"Phosphorylation of DARPP-32 and protein phosphatase inhibitor-1 in rat choroid plexus: regulation by factors other than dopamine.","date":"1992","source":"The Journal of neuroscience : the official journal of the Society for Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/1494946","citation_count":128,"is_preprint":false},{"pmid":"6501303","id":"PMC_6501303","title":"DARPP-32, a dopamine- and adenosine 3':5'-monophosphate-regulated neuronal phosphoprotein. II. Comparison of the kinetics of phosphorylation of DARPP-32 and phosphatase inhibitor 1.","date":"1984","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/6501303","citation_count":128,"is_preprint":false},{"pmid":"10075680","id":"PMC_10075680","title":"Characterization of the inhibition of protein phosphatase-1 by DARPP-32 and inhibitor-2.","date":"1999","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/10075680","citation_count":127,"is_preprint":false},{"pmid":"10377350","id":"PMC_10377350","title":"Expression of the striatal DARPP-32/ARPP-21 phenotype in GABAergic neurons requires neurotrophins in vivo and in vitro.","date":"1999","source":"The Journal of neuroscience : the official journal of the Society for Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/10377350","citation_count":126,"is_preprint":false},{"pmid":"10805695","id":"PMC_10805695","title":"D(1) dopamine receptor activation reduces GABA(A) receptor currents in neostriatal neurons through a PKA/DARPP-32/PP1 signaling cascade.","date":"2000","source":"Journal of neurophysiology","url":"https://pubmed.ncbi.nlm.nih.gov/10805695","citation_count":123,"is_preprint":false},{"pmid":"12068305","id":"PMC_12068305","title":"DARPP-32 and regulation of the ethanol sensitivity of NMDA receptors in the nucleus accumbens.","date":"2002","source":"Nature neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/12068305","citation_count":120,"is_preprint":false},{"pmid":"32768595","id":"PMC_32768595","title":"Loss of HIF1A From Pancreatic Cancer Cells Increases Expression of PPP1R1B and Degradation of p53 to Promote Invasion and Metastasis.","date":"2020","source":"Gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/32768595","citation_count":119,"is_preprint":false},{"pmid":"2573060","id":"PMC_2573060","title":"Dopamine- and cAMP-regulated phosphoprotein (DARPP-32) and dopamine DA1 agonist-sensitive Na+,K+-ATPase in renal tubule cells.","date":"1989","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/2573060","citation_count":110,"is_preprint":false},{"pmid":"2191086","id":"PMC_2191086","title":"Distribution of DARPP-32 in the basal ganglia: an electron microscopic study.","date":"1990","source":"Journal of neurocytology","url":"https://pubmed.ncbi.nlm.nih.gov/2191086","citation_count":107,"is_preprint":false},{"pmid":"10217279","id":"PMC_10217279","title":"Role of calcineurin and protein phosphatase-2A in the regulation of DARPP-32 dephosphorylation in neostriatal neurons.","date":"1999","source":"Journal of neurochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/10217279","citation_count":106,"is_preprint":false},{"pmid":"9108011","id":"PMC_9108011","title":"Characterization of the interaction between DARPP-32 and protein phosphatase 1 (PP-1): DARPP-32 peptides antagonize the interaction of PP-1 with binding proteins.","date":"1997","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/9108011","citation_count":103,"is_preprint":false},{"pmid":"10669419","id":"PMC_10669419","title":"Requirement for DARPP-32 in progesterone-facilitated sexual receptivity in female rats and mice.","date":"2000","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/10669419","citation_count":102,"is_preprint":false},{"pmid":"11117485","id":"PMC_11117485","title":"N-Acetylaspartate and DARPP-32 levels decrease in the corpus striatum of Huntington's disease mice.","date":"2000","source":"Neuroreport","url":"https://pubmed.ncbi.nlm.nih.gov/11117485","citation_count":102,"is_preprint":false},{"pmid":"3511054","id":"PMC_3511054","title":"DARPP-32, a dopamine- and cyclic AMP-regulated neuronal phosphoprotein. Primary structure and homology with protein phosphatase inhibitor-1.","date":"1986","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/3511054","citation_count":99,"is_preprint":false},{"pmid":"15657149","id":"PMC_15657149","title":"Glutamate regulation of DARPP-32 phosphorylation in neostriatal neurons involves activation of multiple signaling cascades.","date":"2005","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/15657149","citation_count":99,"is_preprint":false},{"pmid":"15464122","id":"PMC_15464122","title":"The role of DARPP-32 in the actions of drugs of abuse.","date":"2004","source":"Neuropharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/15464122","citation_count":98,"is_preprint":false},{"pmid":"12124342","id":"PMC_12124342","title":"Gastric cancers overexpress DARPP-32 and a novel isoform, t-DARPP.","date":"2002","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/12124342","citation_count":95,"is_preprint":false},{"pmid":"11880652","id":"PMC_11880652","title":"DARPP-32 mediates serotonergic neurotransmission in the forebrain.","date":"2002","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/11880652","citation_count":93,"is_preprint":false},{"pmid":"17535922","id":"PMC_17535922","title":"The B''/PR72 subunit mediates Ca2+-dependent dephosphorylation of DARPP-32 by protein phosphatase 2A.","date":"2007","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/17535922","citation_count":84,"is_preprint":false},{"pmid":"16123776","id":"PMC_16123776","title":"Phosphorylation of DARPP-32 at Threonine-34 is required for cocaine action.","date":"2006","source":"Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/16123776","citation_count":83,"is_preprint":false},{"pmid":"15010812","id":"PMC_15010812","title":"Evolutionary recombination hotspot around GSDML-GSDM locus is closely linked to the oncogenomic recombination hotspot around the PPP1R1B-ERBB2-GRB7 amplicon.","date":"2004","source":"International journal of oncology","url":"https://pubmed.ncbi.nlm.nih.gov/15010812","citation_count":83,"is_preprint":false},{"pmid":"1328330","id":"PMC_1328330","title":"Immunocytochemical localization of DARPP-32, a dopamine and cyclic-AMP-regulated phosphoprotein, in the primate brain.","date":"1992","source":"The Journal of comparative neurology","url":"https://pubmed.ncbi.nlm.nih.gov/1328330","citation_count":75,"is_preprint":false},{"pmid":"2145398","id":"PMC_2145398","title":"Characterization in mammalian brain of a DARPP-32 serine kinase identical to casein kinase II.","date":"1990","source":"Journal of neurochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/2145398","citation_count":72,"is_preprint":false},{"pmid":"12739007","id":"PMC_12739007","title":"MGC9753 gene, located within PPP1R1B-STARD3-ERBB2-GRB7 amplicon on human chromosome 17q12, encodes the seven-transmembrane receptor with extracellular six-cystein domain.","date":"2003","source":"International journal of oncology","url":"https://pubmed.ncbi.nlm.nih.gov/12739007","citation_count":71,"is_preprint":false},{"pmid":"18554320","id":"PMC_18554320","title":"Enhanced CREB and DARPP-32 phosphorylation in the nucleus accumbens and CREB, ERK, and GluR1 phosphorylation in the dorsal hippocampus is associated with cocaine-conditioned place preference behavior.","date":"2008","source":"Journal of neurochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/18554320","citation_count":71,"is_preprint":false},{"pmid":"30997746","id":"PMC_30997746","title":"LncRNA KCNQ1OT1 enhanced the methotrexate resistance of colorectal cancer cells by regulating miR-760/PPP1R1B via the cAMP signalling pathway.","date":"2019","source":"Journal of cellular and molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/30997746","citation_count":63,"is_preprint":false},{"pmid":"19651774","id":"PMC_19651774","title":"Wnt-5a-induced phosphorylation of DARPP-32 inhibits breast cancer cell migration in a CREB-dependent manner.","date":"2009","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/19651774","citation_count":63,"is_preprint":false},{"pmid":"10103106","id":"PMC_10103106","title":"Neuronal and behavioural abnormalities in striatal function in DARPP-32-mutant mice.","date":"1999","source":"The European journal of neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/10103106","citation_count":62,"is_preprint":false},{"pmid":"23295814","id":"PMC_23295814","title":"Revisiting DARPP-32 in postmortem human brain: changes in schizophrenia and bipolar disorder and genetic associations with t-DARPP-32 expression.","date":"2013","source":"Molecular psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/23295814","citation_count":60,"is_preprint":false},{"pmid":"16061638","id":"PMC_16061638","title":"Darpp-32: a novel antiapoptotic gene in upper gastrointestinal carcinomas.","date":"2005","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/16061638","citation_count":57,"is_preprint":false},{"pmid":"19463699","id":"PMC_19463699","title":"The biological basis of anger: associations with the gene coding for DARPP-32 (PPP1R1B) and with amygdala volume.","date":"2009","source":"Behavioural brain research","url":"https://pubmed.ncbi.nlm.nih.gov/19463699","citation_count":57,"is_preprint":false},{"pmid":"21345011","id":"PMC_21345011","title":"Purmorphamine increases DARPP-32 differentiation in human striatal neural stem cells through the Hedgehog pathway.","date":"2011","source":"Stem cells and development","url":"https://pubmed.ncbi.nlm.nih.gov/21345011","citation_count":56,"is_preprint":false},{"pmid":"21833500","id":"PMC_21833500","title":"Phosphodiesterase 4 inhibition enhances the dopamine D1 receptor/PKA/DARPP-32 signaling cascade in frontal cortex.","date":"2011","source":"Psychopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/21833500","citation_count":54,"is_preprint":false},{"pmid":"8120638","id":"PMC_8120638","title":"Expression of mRNAs encoding ARPP-16/19, ARPP-21, and DARPP-32 in human brain tissue.","date":"1994","source":"The Journal of neuroscience : the official journal of the Society for Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/8120638","citation_count":53,"is_preprint":false},{"pmid":"2160041","id":"PMC_2160041","title":"Distribution and cellular localization of DARPP-32 mRNA in rat brain.","date":"1990","source":"Brain research. Molecular brain research","url":"https://pubmed.ncbi.nlm.nih.gov/2160041","citation_count":52,"is_preprint":false},{"pmid":"16730373","id":"PMC_16730373","title":"Psychoactive drugs and regulation of the cAMP/PKA/DARPP-32 cascade in striatal medium spiny neurons.","date":"2006","source":"Neuroscience and biobehavioral reviews","url":"https://pubmed.ncbi.nlm.nih.gov/16730373","citation_count":51,"is_preprint":false},{"pmid":"10837805","id":"PMC_10837805","title":"DARPP-32 knockout mice exhibit impaired reversal learning in a discriminated operant task.","date":"2000","source":"Brain research","url":"https://pubmed.ncbi.nlm.nih.gov/10837805","citation_count":51,"is_preprint":false},{"pmid":"22559203","id":"PMC_22559203","title":"DRD2 and PPP1R1B (DARPP-32) polymorphisms independently confer increased risk for autism spectrum disorders and additively predict affected status in male-only affected sib-pair families.","date":"2012","source":"Behavioral and brain functions : BBF","url":"https://pubmed.ncbi.nlm.nih.gov/22559203","citation_count":50,"is_preprint":false},{"pmid":"29221855","id":"PMC_29221855","title":"Toll-like receptor-4 regulates anxiety-like behavior and DARPP-32 phosphorylation.","date":"2017","source":"Brain, behavior, and immunity","url":"https://pubmed.ncbi.nlm.nih.gov/29221855","citation_count":48,"is_preprint":false},{"pmid":"27590997","id":"PMC_27590997","title":"Helicobacter pylori-induced cell death is counteracted by NF-κB-mediated transcription of DARPP-32.","date":"2016","source":"Gut","url":"https://pubmed.ncbi.nlm.nih.gov/27590997","citation_count":48,"is_preprint":false},{"pmid":"17027969","id":"PMC_17027969","title":"Phosphorylation of DARPP-32 regulates breast cancer cell migration downstream of the receptor tyrosine kinase DDR1.","date":"2006","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/17027969","citation_count":47,"is_preprint":false},{"pmid":"3335843","id":"PMC_3335843","title":"DARPP-32 and phosphatase inhibitor-1, two structurally related inhibitors of protein phosphatase-1, are both present in striatonigral neurons.","date":"1988","source":"Journal of neurochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/3335843","citation_count":47,"is_preprint":false},{"pmid":"1979497","id":"PMC_1979497","title":"Rat DARPP-32: cloning, sequencing, and characterization of the cDNA.","date":"1990","source":"Journal of molecular neuroscience : MN","url":"https://pubmed.ncbi.nlm.nih.gov/1979497","citation_count":47,"is_preprint":false},{"pmid":"19301121","id":"PMC_19301121","title":"Both t-Darpp and DARPP-32 can cause resistance to trastuzumab in breast cancer cells and are frequently expressed in primary breast cancers.","date":"2009","source":"Breast cancer research and treatment","url":"https://pubmed.ncbi.nlm.nih.gov/19301121","citation_count":47,"is_preprint":false},{"pmid":"19593441","id":"PMC_19593441","title":"Darpp-32 and its truncated variant t-Darpp have antagonistic effects on breast cancer cell growth and herceptin resistance.","date":"2009","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/19593441","citation_count":44,"is_preprint":false},{"pmid":"15196506","id":"PMC_15196506","title":"DARPP-32 and modulation of cAMP signaling: involvement in motor control and levodopa-induced dyskinesia.","date":"2004","source":"Parkinsonism & related disorders","url":"https://pubmed.ncbi.nlm.nih.gov/15196506","citation_count":43,"is_preprint":false},{"pmid":"25779598","id":"PMC_25779598","title":"Gastric tumour-derived ANGPT2 regulation by DARPP-32 promotes angiogenesis.","date":"2015","source":"Gut","url":"https://pubmed.ncbi.nlm.nih.gov/25779598","citation_count":43,"is_preprint":false},{"pmid":"24395794","id":"PMC_24395794","title":"Feedback regulation mediated by Bcl-2 and DARPP-32 regulates inositol 1,4,5-trisphosphate receptor phosphorylation and promotes cell survival.","date":"2014","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/24395794","citation_count":43,"is_preprint":false},{"pmid":"3339428","id":"PMC_3339428","title":"Cloning of cDNA for DARPP-32, a dopamine- and cyclic AMP-regulated neuronal phosphoprotein.","date":"1988","source":"The Journal of neuroscience : the official journal of the Society for Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/3339428","citation_count":42,"is_preprint":false},{"pmid":"19059449","id":"PMC_19059449","title":"The leukocytes expressing DARPP-32 are reduced in patients with schizophrenia and bipolar disorder.","date":"2008","source":"Progress in neuro-psychopharmacology & biological psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/19059449","citation_count":41,"is_preprint":false},{"pmid":"24276243","id":"PMC_24276243","title":"PPP1R1B-STARD3 chimeric fusion transcript in human gastric cancer promotes tumorigenesis through activation of PI3K/AKT signaling.","date":"2013","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/24276243","citation_count":39,"is_preprint":false},{"pmid":"17251906","id":"PMC_17251906","title":"Activation of the cAMP/PKA/DARPP-32 signaling pathway is required for morphine psychomotor stimulation but not for morphine reward.","date":"2007","source":"Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/17251906","citation_count":39,"is_preprint":false},{"pmid":"21741919","id":"PMC_21741919","title":"DARPP-32 increases interactions between epidermal growth factor receptor and ERBB3 to promote tumor resistance to gefitinib.","date":"2011","source":"Gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/21741919","citation_count":38,"is_preprint":false},{"pmid":"10336688","id":"PMC_10336688","title":"Mu- and delta-opioid receptor agonists inhibit DARPP-32 phosphorylation in distinct populations of striatal projection neurons.","date":"1999","source":"The European journal of neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/10336688","citation_count":38,"is_preprint":false},{"pmid":"31953255","id":"PMC_31953255","title":"Ppp1r1b-lncRNA inhibits PRC2 at myogenic regulatory genes to promote cardiac and skeletal muscle development in mouse and human.","date":"2020","source":"RNA (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/31953255","citation_count":37,"is_preprint":false},{"pmid":"28052701","id":"PMC_28052701","title":"Potential for targeting dopamine/DARPP-32 signaling in neuropsychiatric and neurodegenerative disorders.","date":"2017","source":"Expert opinion on therapeutic targets","url":"https://pubmed.ncbi.nlm.nih.gov/28052701","citation_count":35,"is_preprint":false},{"pmid":"10854268","id":"PMC_10854268","title":"Dopamine D(1) receptor-induced gene transcription is modulated by DARPP-32.","date":"2000","source":"Journal of neurochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/10854268","citation_count":35,"is_preprint":false},{"pmid":"30043390","id":"PMC_30043390","title":"DARPP-32 in the orchestration of responses to positive natural stimuli.","date":"2018","source":"Journal of neurochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/30043390","citation_count":34,"is_preprint":false},{"pmid":"26639316","id":"PMC_26639316","title":"DARPP-32 interaction with adducin may mediate rapid environmental effects on striatal neurons.","date":"2015","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/26639316","citation_count":34,"is_preprint":false},{"pmid":"16040813","id":"PMC_16040813","title":"Nicotine regulates DARPP-32 (dopamine- and cAMP-regulated phosphoprotein of 32 kDa) phosphorylation at multiple sites in neostriatal neurons.","date":"2005","source":"The Journal of pharmacology and experimental therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/16040813","citation_count":33,"is_preprint":false},{"pmid":"23543809","id":"PMC_23543809","title":"DARPP-32 to quantify intracerebral hemorrhage-induced neuronal death in basal ganglia.","date":"2012","source":"Translational stroke research","url":"https://pubmed.ncbi.nlm.nih.gov/23543809","citation_count":31,"is_preprint":false},{"pmid":"26872373","id":"PMC_26872373","title":"DARPP-32: from neurotransmission to cancer.","date":"2016","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/26872373","citation_count":30,"is_preprint":false},{"pmid":"17686497","id":"PMC_17686497","title":"Regulation of DARPP-32 phosphorylation by Delta9-tetrahydrocannabinol.","date":"2007","source":"Neuropharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/17686497","citation_count":30,"is_preprint":false},{"pmid":"10799680","id":"PMC_10799680","title":"DARPP-32 and CREB are present in type 2 iodothyronine deiodinase-producing tanycytes: implications for the regulation of type 2 deiodinase activity.","date":"2000","source":"Brain research","url":"https://pubmed.ncbi.nlm.nih.gov/10799680","citation_count":30,"is_preprint":false},{"pmid":"31235784","id":"PMC_31235784","title":"Activation of IGF1R by DARPP-32 promotes STAT3 signaling in gastric cancer cells.","date":"2019","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/31235784","citation_count":29,"is_preprint":false},{"pmid":"16850143","id":"PMC_16850143","title":"DRD2/DARPP-32 expression correlates with lymph node metastasis and tumor progression in patients with esophageal squamous cell carcinoma.","date":"2006","source":"World journal of surgery","url":"https://pubmed.ncbi.nlm.nih.gov/16850143","citation_count":29,"is_preprint":false},{"pmid":"7931332","id":"PMC_7931332","title":"Phosphorylation of DARPP-32 is regulated by GABA in rat striatum and substantia nigra.","date":"1994","source":"Journal of neurochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/7931332","citation_count":28,"is_preprint":false},{"pmid":"19465068","id":"PMC_19465068","title":"Colocalization of dopamine receptor subtypes with dopamine and cAMP-regulated phosphoprotein (DARPP-32) in rat brain.","date":"2009","source":"Neuroscience research","url":"https://pubmed.ncbi.nlm.nih.gov/19465068","citation_count":27,"is_preprint":false},{"pmid":"29782621","id":"PMC_29782621","title":"DARPP-32 and t-DARPP promote non-small cell lung cancer growth through regulation of IKKα-dependent cell migration.","date":"2018","source":"Communications biology","url":"https://pubmed.ncbi.nlm.nih.gov/29782621","citation_count":26,"is_preprint":false},{"pmid":"15830379","id":"PMC_15830379","title":"DARPP-32 genomic fragments drive Cre expression in postnatal striatum.","date":"2005","source":"Genesis (New York, N.Y. : 2000)","url":"https://pubmed.ncbi.nlm.nih.gov/15830379","citation_count":26,"is_preprint":false},{"pmid":"15188007","id":"PMC_15188007","title":"DARPP-32 expression arises after a phase of dysplasia in oesophageal squamous cell carcinoma.","date":"2004","source":"British journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/15188007","citation_count":26,"is_preprint":false},{"pmid":"23160836","id":"PMC_23160836","title":"Regulation of CXCR4-mediated invasion by DARPP-32 in gastric cancer cells.","date":"2012","source":"Molecular cancer research : MCR","url":"https://pubmed.ncbi.nlm.nih.gov/23160836","citation_count":26,"is_preprint":false},{"pmid":"33706939","id":"PMC_33706939","title":"DARPP-32 40 years later.","date":"2020","source":"Advances in pharmacology (San Diego, Calif.)","url":"https://pubmed.ncbi.nlm.nih.gov/33706939","citation_count":25,"is_preprint":false},{"pmid":"28881851","id":"PMC_28881851","title":"The involvement of DARPP-32 in the pathophysiology of schizophrenia.","date":"2017","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/28881851","citation_count":25,"is_preprint":false},{"pmid":"17763944","id":"PMC_17763944","title":"DARPP-32 and NCS-1 expression is not altered in brains of rats treated with typical or atypical antipsychotics.","date":"2007","source":"Neurochemical research","url":"https://pubmed.ncbi.nlm.nih.gov/17763944","citation_count":25,"is_preprint":false},{"pmid":"8408754","id":"PMC_8408754","title":"Comparison of the immunocytochemical localization of DARPP-32 and I-1 in the amygdala and hippocampus of the rhesus monkey.","date":"1993","source":"The Journal of comparative neurology","url":"https://pubmed.ncbi.nlm.nih.gov/8408754","citation_count":25,"is_preprint":false},{"pmid":"30697741","id":"PMC_30697741","title":"The expression of tyrosine hydroxylase and DARPP-32 in the house crow (Corvus splendens) brain.","date":"2019","source":"The Journal of comparative neurology","url":"https://pubmed.ncbi.nlm.nih.gov/30697741","citation_count":24,"is_preprint":false},{"pmid":"15707466","id":"PMC_15707466","title":"Overexpression of DARPP-32 in colorectal adenocarcinoma.","date":"2005","source":"International journal of clinical practice","url":"https://pubmed.ncbi.nlm.nih.gov/15707466","citation_count":24,"is_preprint":false},{"pmid":"10383649","id":"PMC_10383649","title":"Requirement for DARPP-32 in mediating effect of dopamine D2 receptor activation.","date":"1999","source":"The European journal of neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/10383649","citation_count":24,"is_preprint":false},{"pmid":"26119931","id":"PMC_26119931","title":"Regulation of CD44E by DARPP-32-dependent activation of SRp20 splicing factor in gastric tumorigenesis.","date":"2015","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/26119931","citation_count":24,"is_preprint":false},{"pmid":"30552871","id":"PMC_30552871","title":"Darpp-32 and t-Darpp protein products of PPP1R1B: Old dogs with new tricks.","date":"2018","source":"Biochemical pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/30552871","citation_count":23,"is_preprint":false},{"pmid":"21453742","id":"PMC_21453742","title":"Altered DARPP-32 expression in the superior temporal gyrus in schizophrenia.","date":"2011","source":"Progress in neuro-psychopharmacology & biological psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/21453742","citation_count":23,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":54940,"output_tokens":10500,"usd":0.16116,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":21136,"output_tokens":5052,"usd":0.11599,"stage2_stop_reason":"end_turn"},"total_usd":0.27715,"stage1_batch_id":"msgbatch_01CNoDbkChHEkgrJnL7BwtGJ","stage2_batch_id":"msgbatch_016Y4x9E9Wg5VQDANj9quSQD","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1984,\n      \"finding\": \"Phosphorylated DARPP-32 is a potent inhibitor of protein phosphatase-1 (PP-1) at nanomolar concentrations; inhibitory activity requires the phosphorylated (not dephosphorylated) form of the protein.\",\n      \"method\": \"In vitro phosphatase inhibition assay with purified DARPP-32 and PP-1\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — direct in vitro enzymatic assay with purified components, foundational result replicated across many subsequent studies\",\n      \"pmids\": [\"6087160\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1984,\n      \"finding\": \"DARPP-32 is phosphorylated on a single threonine residue (Thr34) by both cAMP-dependent protein kinase (PKA) and cGMP-dependent protein kinase (PKG) in vitro, with kinetic parameters compatible with a physiological role for both kinases.\",\n      \"method\": \"In vitro kinase assay with purified PKA and PKG; two-dimensional phosphopeptide mapping; stoichiometry determination\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — reconstituted in vitro with purified components, phosphopeptide mapping, replicated in multiple papers\",\n      \"pmids\": [\"6501303\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1984,\n      \"finding\": \"DARPP-32 is phosphorylated in intact striatal cells by dopamine and by 8-bromo-cAMP, and in cell-free preparations by cAMP-dependent protein kinase, establishing a dopamine→cAMP→PKA→DARPP-32 signaling axis in dopaminoceptive neurons.\",\n      \"method\": \"Intact cell radiolabeling with [32P]; cell-free kinase assay\",\n      \"journal\": \"The Journal of neuroscience\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — both cell-free and intact-cell phosphorylation demonstrated, replicated across multiple labs\",\n      \"pmids\": [\"6319627\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1984,\n      \"finding\": \"DARPP-32 is an elongated monomeric protein of 202 residues with a calculated mass of ~22.6 kDa (anomalously high apparent MW on SDS-PAGE); it is highly hydrophilic with a high proline/glutamate content and a stretch of 16 consecutive acidic residues.\",\n      \"method\": \"Protein purification (435-fold), SDS-PAGE, hydrodynamic measurements (Stokes radius, sedimentation coefficient), amino acid composition\",\n      \"journal\": \"The Journal of neuroscience\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — biochemical characterization of purified protein, sequence confirmed in follow-up study\",\n      \"pmids\": [\"6319628\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1986,\n      \"finding\": \"The complete amino acid sequence of bovine DARPP-32 was determined; the phosphorylation site for PKA is Thr34; the NH2-terminal region of DARPP-32 shares significant sequence identity with protein phosphatase inhibitor-1, suggesting a common structural basis for PP-1 inhibitory activity.\",\n      \"method\": \"Protein sequencing by automated Edman degradation of overlapping peptides from multiple enzymatic/chemical cleavages; sequence comparison\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — full primary structure determination by direct protein sequencing\",\n      \"pmids\": [\"3511054\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1989,\n      \"finding\": \"Casein kinase II (CK2) phosphorylates DARPP-32 in vitro at Ser45 and Ser102 (main site in intact cells is Ser102); phosphorylation by CK2 does not directly affect PP-1 inhibitory potency but facilitates subsequent phosphorylation of Thr34 by PKA (~2.2-fold increase in Vmax).\",\n      \"method\": \"In vitro kinase assay with purified CK2; phosphopeptide sequencing; manual Edman degradation; [32P]-labeling of intact caudate-putamen slices; kinetic analysis with synthetic peptides\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro reconstitution with site identification, intact-cell confirmation, and functional consequence measured\",\n      \"pmids\": [\"2557337\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"Cyclin-dependent kinase 5 (Cdk5) phosphorylates DARPP-32 at Thr75 in vitro and in intact brain cells, converting DARPP-32 into an inhibitor of PKA by a competitive mechanism; this is distinct from the PP-1 inhibitory function conferred by Thr34 phosphorylation.\",\n      \"method\": \"In vitro kinase assay; intact brain cell [32P] labeling; Cdk5-specific inhibitor treatment; Cdk5 mutant mice; electrophysiological measurement of voltage-gated Ca2+ currents\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro reconstitution plus intact-cell validation plus genetic (mutant mouse) confirmation, replicated\",\n      \"pmids\": [\"10604473\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"The NH2-terminal motif RKKIQF (residues 6–11) of DARPP-32 is required for PP-1 inhibition; Phe11 and Ile9 play critical roles. Peptides containing this motif antagonize inhibition of PP-1 by phospho-DARPP-32 and compete with PP-1 targeting/binding proteins, suggesting two-site interaction of phospho-DARPP-32 with PP-1 (active-site interaction via phospho-Thr34, and remote-site interaction via RKKIQF motif).\",\n      \"method\": \"Synthetic peptide competition assays; mutagenesis of DARPP-32; in vitro PP-1 inhibition assays\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro reconstitution with systematic mutagenesis and peptide competition, single lab but multiple orthogonal approaches\",\n      \"pmids\": [\"9108011\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"Detailed mutagenesis of phospho-DARPP-32 identified Phe11, Ile9 (critical), Lys7 (lesser), Pro33, Pro35, and phospho-Thr34 as key residues for PP-1 inhibition; the spacing between residues 7–11 and phospho-Thr34 is also important. The KKIQF motif in DARPP-32 and IKGI in inhibitor-2 represent distinct NH2-terminal motifs critical for PP-1 inhibition.\",\n      \"method\": \"Site-directed mutagenesis; in vitro PP-1 inhibition assays (IC50 measurements); peptide competition\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — systematic mutagenesis with quantitative enzyme inhibition measurements\",\n      \"pmids\": [\"10075680\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"Dopamine exerts bidirectional control of DARPP-32 phosphorylation: D1 receptor activation increases Thr34 phosphorylation (via PKA), while D2 receptor activation decreases Thr34 phosphorylation via a calcium-dependent calcineurin pathway (blocked by cyclosporin A and Ca2+-free/EGTA medium).\",\n      \"method\": \"Mouse striatal slice preparation; [32P] phosphorylation assay; pharmacological D1/D2 agonist/antagonist treatment; calcineurin inhibitor (cyclosporin A); Ca2+-free medium\",\n      \"journal\": \"The Journal of neuroscience\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple pharmacological tools in intact tissue, replicated across subsequent studies\",\n      \"pmids\": [\"9334390\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"Calcineurin (PP2B) is the primary phosphatase responsible for dephosphorylating Thr34-phospho-DARPP-32 in neostriatal neurons, acting synergistically with PP2A (not PP-1); cyclosporin A (calcineurin inhibitor) produced a ~17-fold increase in phospho-DARPP-32 in striatal slices.\",\n      \"method\": \"Mouse neostriatal slice phosphorylation assay; pharmacological inhibitors (cyclosporin A, okadaic acid, calyculin A); Ca2+-free/EGTA medium\",\n      \"journal\": \"Journal of neurochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple selective inhibitors used in intact tissue, replicated in subsequent studies\",\n      \"pmids\": [\"10217279\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"DARPP-32 knockout mice show profound deficits in molecular, electrophysiological, and behavioral responses to dopamine, drugs of abuse, and antipsychotic medication, establishing DARPP-32 as central to the efficacy of dopaminergic neurotransmission in vivo.\",\n      \"method\": \"Targeted gene disruption (knockout mouse); behavioral assays; electrophysiology; biochemical assays\",\n      \"journal\": \"Science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — clean genetic KO with multiple defined phenotypic readouts across labs\",\n      \"pmids\": [\"9694658\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"D1 dopamine receptor stimulation reduces GABA-evoked currents in neostriatal medium spiny neurons through a PKA/DARPP-32/PP1 signaling cascade targeting GABA(A) receptor beta1/beta3 subunits; phosphorylation of beta1/beta3 subunits was attenuated in DARPP-32 mutant neurons.\",\n      \"method\": \"Whole-cell voltage-clamp recordings; immunoprecipitation of radiolabeled proteins; DARPP-32 knockout mice; single-cell RT-PCR\",\n      \"journal\": \"Journal of neurophysiology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — electrophysiology combined with biochemical IP and genetic KO, multiple methods\",\n      \"pmids\": [\"10805695\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"DARPP-32 is required for progesterone-facilitated sexual receptivity in female rats and mice; progesterone increases hypothalamic cAMP levels and PKA activity, leading to Thr34-DARPP-32 phosphorylation; DARPP-32 is an obligate intermediate in progestin receptor-regulated sexual behavior.\",\n      \"method\": \"Antisense oligonucleotides to DARPP-32 in rats; DARPP-32 null mutant mice; behavioral assays; cAMP and PKA activity measurements; phospho-DARPP-32 immunoblot\",\n      \"journal\": \"Science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — antisense knockdown in rats corroborated by genetic KO in mice with defined behavioral phenotype\",\n      \"pmids\": [\"10669419\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"DARPP-32 mediates the stimulant action of caffeine (via adenosine A2A receptor blockade) by increasing Thr75 phosphorylation; this occurs through inhibition of PP2A-catalyzed dephosphorylation of Thr75 rather than through stimulation of Cdk5.\",\n      \"method\": \"DARPP-32 knockout mice; locomotor activity assays; phospho-specific immunoblot of striatal tissue; pharmacological A2A antagonist/agonist treatment\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic KO with defined behavioral and biochemical phenotype, mechanism of Thr75 regulation dissected pharmacologically\",\n      \"pmids\": [\"12181566\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"Fluoxetine regulates DARPP-32 phosphorylation at multiple sites (increases Thr34 and Ser137, decreases Thr75) in prefrontal cortex, hippocampus, and striatum; DARPP-32 mediates fluoxetine-induced phosphorylation of AMPA receptor GluR1 at Ser845 and the antidepressant behavioral response, as shown by attenuation in DARPP-32 knockout mice.\",\n      \"method\": \"In vivo drug administration; DARPP-32 knockout mice; phospho-specific immunoblots; animal test of antidepressant efficacy\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic KO with biochemical and behavioral phenotypes, multiple phosphorylation sites examined\",\n      \"pmids\": [\"11880651\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"Prior D1 receptor activation and consequent DARPP-32 phosphorylation (with subsequent NR1-NMDA receptor phosphorylation) strongly reduces ethanol inhibition of NMDA responses in nucleus accumbens; this regulation was absent in DARPP-32 knockout mice.\",\n      \"method\": \"Rat/mouse nucleus accumbens slice electrophysiology; DARPP-32 knockout mice; pharmacological D1 receptor activation\",\n      \"journal\": \"Nature neuroscience\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — electrophysiology in intact tissue plus genetic KO confirmation\",\n      \"pmids\": [\"12068305\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"Glutamate regulates DARPP-32 phosphorylation at Thr34 and Thr75 through at least five distinct signaling cascades with different time dependencies: (1) NMDA/AMPA/mGluR5→nNOS/NO/cGMP/PKG→Thr34 increase; (2) NMDA/AMPA→Ca2+/PP2B→Thr34 decrease; (3) mGluR5/PLC/ERK→Thr34 rephosphorylation; (4) NMDA/AMPA→Ca2+/PP2A→Thr75 decrease; (5) mGluR1/PLC→Thr75 increase.\",\n      \"method\": \"Mouse neostriatal slice phosphorylation assay; selective receptor antagonists; phospho-specific immunoblots; NOS/NO pathway inhibitors\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — systematic pharmacological dissection of multiple signaling arms in intact tissue, single lab with multiple orthogonal inhibitors\",\n      \"pmids\": [\"15657149\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"The PR72/B'' regulatory subunit of PP2A mediates Ca2+-dependent dephosphorylation of DARPP-32 at Thr75; PR72 contains two EF-hand Ca2+-binding sites and EF-hand 1 is necessary for Ca2+-dependent regulation of PP2A activity both in vitro and in vivo; this PP2A/PR72 complex is required for glutamate (AMPA/NMDA receptor)-induced Thr75 dephosphorylation.\",\n      \"method\": \"Overexpression and RNAi knockdown of PR72; in vitro PP2A assay; mutagenesis of EF-hand Ca2+-binding sites; striatal slice phosphorylation assay; glutamate receptor pharmacology\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — mutagenesis of regulatory domain combined with RNAi and in vitro assay, single lab with multiple orthogonal methods\",\n      \"pmids\": [\"17535922\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Phosphorylation of DARPP-32 at Thr34 is required for cocaine-induced conditioned place preference, acute locomotor response, and immediate early gene induction (c-fos, arc) in striatum; Thr75 phosphorylation is required for locomotor sensitization to repeated cocaine but not for acute locomotor response or conditioned place preference.\",\n      \"method\": \"Knock-in mice with T34A or T75A point mutations in DARPP-32; behavioral assays (CPP, locomotor activity, sensitization); striatal gene expression analysis\",\n      \"journal\": \"Neuropsychopharmacology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — site-specific knock-in mutations with multiple behavioral and biochemical readouts\",\n      \"pmids\": [\"16123776\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"Sensitized cAMP/PKA/DARPP-32 signaling in L-DOPA-induced dyskinesia leads to sequential phosphorylation of ERK1/2, MSK-1, and histone H3 in striatal medium spiny neurons; genetic inactivation of DARPP-32 reduces dyskinesia, and pharmacological inhibition of MEK counteracts LID induction.\",\n      \"method\": \"DARPP-32 knockout mice; L-DOPA-treated mouse model of dyskinesia; phospho-specific immunoblots; MEK inhibitor (SL327) treatment; c-Fos expression analysis\",\n      \"journal\": \"The Journal of neuroscience\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic KO plus pharmacological intervention with defined biochemical cascade and behavioral phenotype\",\n      \"pmids\": [\"17596448\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Cocaine (psychostimulant) and haloperidol (antipsychotic) exert opposing, cell-type-specific effects on DARPP-32 Thr34 phosphorylation: cocaine preferentially increases phospho-Thr34 in striatonigral (D1) neurons, while haloperidol preferentially increases it in striatopallidal (D2) neurons.\",\n      \"method\": \"BAC transgenic mice enabling cell-type-selective DARPP-32 phosphorylation analysis; phospho-specific immunoblots from FACS-sorted neuronal populations\",\n      \"journal\": \"Nature neuroscience\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — novel cell-type-selective genetic tool combined with biochemical readout, multiple drugs tested\",\n      \"pmids\": [\"18622401\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"Wnt-5a triggers cAMP elevation and Thr34-DARPP-32 phosphorylation in breast cancer cells via Frizzled-3/Gαs/PKA signaling; phospho-Thr34-DARPP-32 interacts with PP1, potentiates CREB phosphorylation, reduces Cdc42 activity and filopodia formation, and thereby inhibits MCF-7 breast cancer cell migration.\",\n      \"method\": \"Recombinant Wnt-5a treatment; siRNA knockdown of Frizzled-3, Gαs, DARPP-32; PKA inhibitors; dominant-negative CREB expression; cAMP imaging; Cdc42 activity assay; phalloidin staining; migration assay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal approaches (siRNA, dominant-negative, imaging, activity assays) in single lab\",\n      \"pmids\": [\"19651774\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"DARPP-32 expression in non-transformed mammary cells inhibits cell migration downstream of the collagen receptor DDR1; phosphorylation of Thr34 (but not Thr75) is necessary for this antimigratory effect; co-expression of DDR1 and DARPP-32 is required for migration inhibition.\",\n      \"method\": \"Transfection of MCF7 and MDA-MB-231 cells with DARPP-32 mutants; cell migration assay; immunoblot analysis\",\n      \"journal\": \"Experimental cell research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — site-specific mutagenesis with functional readout, single lab, single method for migration\",\n      \"pmids\": [\"17027969\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Bcl-2 binds DARPP-32 and docks it with calcineurin (CaN) in a complex on the InsP3R, creating a negative feedback loop: PKA phosphorylates InsP3R and DARPP-32; phospho-DARPP-32 inhibits PP1, enhancing InsP3R phosphorylation and Ca2+ release; elevated Ca2+ activates CaN, which dephosphorylates DARPP-32 to dampen further Ca2+ release. Knockdown of Bcl-2 or DARPP-32 disrupts this feedback and increases apoptosis.\",\n      \"method\": \"Co-immunoprecipitation; RNAi knockdown of Bcl-2 and DARPP-32; Ca2+ measurement; apoptosis assay; T-cell activation experiments\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal Co-IP establishing complex, functional consequences via RNAi, single lab\",\n      \"pmids\": [\"24395794\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"DARPP-32 interacts physically with adducins (cytoskeletal actin-capping proteins) via the adducin MARCKS domain; this interaction is modulated by DARPP-32 Ser97 phosphorylation. Phospho-Thr75-DARPP-32 facilitates β-adducin Ser713 phosphorylation through inhibition of a PKA/PP2A cascade. This pathway is implicated in environmental enrichment-induced changes in nucleus accumbens dendritic spines and cocaine locomotor responses.\",\n      \"method\": \"Co-immunoprecipitation; DARPP-32 T75A knock-in mice; phospho-specific immunoblots; dendritic spine analysis; cocaine locomotor assay\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal Co-IP plus knock-in mouse with defined structural and behavioral phenotype, single lab\",\n      \"pmids\": [\"26639316\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"DARPP-32 colocalizes with EGFR on the cell membrane in a complex with EGFR and ERBB3; overexpression of DARPP-32 stabilizes EGFR, increases EGFR-ERBB3 interaction and phosphorylation, activates AKT (Ser473), and confers resistance to gefitinib in gastric cancer cells.\",\n      \"method\": \"Co-immunoprecipitation; immunofluorescence colocalization; clonogenic survival assay; Annexin-V apoptosis assay; shRNA knockdown; mouse xenograft model\",\n      \"journal\": \"Gastroenterology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP establishing complex plus functional knockdown/overexpression with in vivo validation, single lab\",\n      \"pmids\": [\"21741919\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"DARPP-32 physically interacts with IGF1R and promotes its phosphorylation (Y1135), leading to activation of downstream SRC and STAT3 (Y705 phosphorylation, nuclear localization, transcription activation); in DARPP-32 knockout/TFF1 knockout double-mutant mice, IGF1R and STAT3 phosphorylation is absent, and gastric neoplasia development is delayed.\",\n      \"method\": \"Proximity ligation assay; co-immunoprecipitation; 3D gastric organoids; double-knockout mouse model (TFF1 KO × DARPP-32 KO); immunohistochemistry of human gastric cancer tissue arrays\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — proximity ligation + Co-IP establishing complex, genetic in vivo validation, single lab\",\n      \"pmids\": [\"31235784\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"DARPP-32 regulates ANGPT2-mediated tumor angiogenesis through a STAT3-dependent (not NF-κB-dependent) mechanism; this effect is independent of Thr34-mediated PP1 inhibition, as T34A mutant and truncated t-DARPP produce similar ANGPT2 induction; DARPP-32 activates STAT3 phosphorylation and nuclear localization.\",\n      \"method\": \"DARPP-32 overexpression/knockdown; quantitative RT-PCR; immunoblot; luciferase reporter; HUVEC tube formation assay; STAT3 inhibitor/siRNA; in vivo xenograft tumor model; immunohistochemistry of human gastric cancer tissues\",\n      \"journal\": \"Gut\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple cell-based assays plus in vivo xenograft with STAT3 mechanistic dissection, single lab\",\n      \"pmids\": [\"25779598\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"DARPP-32 forms a protein complex with SRp20 splicing factor (co-immunoprecipitation), regulates SRp20 protein stability (via alternative splicing inhibitor digitoxin experiments), and thereby controls CD44E (CD44 V8-V10) splice variant expression to promote gastric cancer cell proliferation in vitro and tumor growth in vivo.\",\n      \"method\": \"siRNA/shRNA knockdown; splicing luciferase reporter; co-immunoprecipitation; immunoprecipitation with digitoxin; tumor xenograft model; SRp20 reconstitution rescue experiment; human gastric cancer tissue analysis\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP establishing complex, functional rescue experiment with SRp20 reconstitution, in vivo validation, single lab\",\n      \"pmids\": [\"26119931\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"DARPP-32 forms a protein complex with CXCR4 (co-immunoprecipitation and immunofluorescence); DARPP-32 prolongs CXCR4 protein half-life, reduces CXCL12-induced CXCR4 ubiquitination, and promotes gastric cancer cell invasion through CXCR4-dependent activation of the MT1-MMP/MMP-2 pathway.\",\n      \"method\": \"Reciprocal co-immunoprecipitation; immunofluorescence; CXCR4 antagonist (AMD3100) and siRNA; MMP-2 activity assay; Matrigel invasion assay; impedance-based invasion assay; DARPP-32 overexpression/knockdown\",\n      \"journal\": \"Molecular cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal Co-IP establishing complex, functional validation with antagonist and siRNA, single lab\",\n      \"pmids\": [\"23160836\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"DARPP-32 physically interacts with IKKα (inhibitory kappa B kinase-α), and this interaction promotes NSCLC cell migration through non-canonical NF-κB2 signaling; abrogation of DARPP-32 expression reduces tumor growth in orthotopic mouse models.\",\n      \"method\": \"Co-immunoprecipitation; shRNA knockdown; orthotopic mouse tumor model; NF-κB2 signaling analysis; patient tissue immunohistochemistry\",\n      \"journal\": \"Communications biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP establishing novel interaction, in vivo orthotopic model, single lab\",\n      \"pmids\": [\"29782621\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"H. pylori infection induces DARPP-32 expression through NF-κB transcriptional activation: ChIP and deletion-based luciferase reporter identified the DARPP-32 promoter region −996 to −1008 bp (containing NF-κB-binding sites) as the key regulatory element; DARPP-32 induction counteracts H. pylori-induced cell death through AKT activation.\",\n      \"method\": \"Luciferase reporter assays with DARPP-32 promoter deletions; ChIP assay; H. pylori infection of gastric cancer cells and mice; ATP-Glo and clonogenic survival assays; immunohistochemistry of gastric cancer tissues\",\n      \"journal\": \"Gut\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP confirming NF-κB binding at defined promoter region plus functional cell survival assays, single lab\",\n      \"pmids\": [\"27590997\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Loss of HIF1A in pancreatic cancer cells increases PPP1R1B expression; elevated PPP1R1B promotes p53 degradation by stabilizing phosphorylation of MDM2 at Ser166; knockdown of PPP1R1B reduces the ability of pancreatic cancer cells to form lung metastases in mice.\",\n      \"method\": \"KPC mouse models with pancreas-specific HIF1A deletion; shRNA knockdown of PPP1R1B; immunoblot; in vivo lung metastasis assay; liquid chromatography-mass spectrometry\",\n      \"journal\": \"Gastroenterology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo genetic model with mechanistic biochemical follow-up, single lab\",\n      \"pmids\": [\"32768595\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"DARPP-32 and its truncated isoform t-DARPP exert antiapoptotic effects in gastrointestinal cancer cells through a p53-independent mechanism involving preservation of mitochondrial transmembrane potential and increased Bcl-2 levels; antiapoptotic activity required intact phosphorylation sites.\",\n      \"method\": \"Overexpression of DARPP-32 and t-DARPP with phosphorylation site mutations; TUNEL and Annexin-V apoptosis assays; mitochondrial membrane potential assay; siRNA knockdown; luciferase reporters for p53/p21\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — mutagenesis with functional apoptosis assays, phosphorylation site dependency shown, single lab\",\n      \"pmids\": [\"16061638\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"The truncated isoform t-DARPP lacks the Thr34 phosphorylation site (PP-1 inhibitory site) but retains the Thr75 site (PKA inhibitory site); both full-length DARPP-32 and t-DARPP are overexpressed in gastric cancers.\",\n      \"method\": \"cDNA cloning; RT-PCR; Western blotting; tumor tissue array analysis\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — molecular characterization of novel isoform with structural inference, replicated in multiple subsequent studies\",\n      \"pmids\": [\"12124342\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"t-DARPP overexpression in breast cancer cells is sufficient to confer trastuzumab resistance and sustain Akt phosphorylation; the Thr75 residue in t-DARPP is required for both Akt activation and trastuzumab resistance; full-length DARPP-32 co-expression reverses these effects. t-DARPP also increases CREB binding activity.\",\n      \"method\": \"Gene silencing (RNAi); transfection of t-DARPP and DARPP-32 cDNAs; T75 mutagenesis; trastuzumab resistance assay; Akt phosphorylation immunoblot; CREB DNA binding assay\",\n      \"journal\": \"Breast cancer research and treatment / PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — site-specific mutagenesis with functional drug resistance readout, corroborated by two independent labs (PMID 19301121 and 19593441)\",\n      \"pmids\": [\"19301121\", \"19593441\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1990,\n      \"finding\": \"Casein kinase II activity identified in caudate-putamen cytosol phosphorylates DARPP-32 on the same seryl residue as purified CK2; CK2-like immunoreactivity colocalizes with DARPP-32 in medium-sized striatonigral neurons; ~45% of total CK2 activity is cytosolic in rat caudate-putamen.\",\n      \"method\": \"Biochemical kinase characterization; excitotoxic lesions (kainic acid); immunocytochemistry; subcellular fractionation\",\n      \"journal\": \"Journal of neurochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — biochemical identity of endogenous kinase established with multiple criteria plus cellular colocalization\",\n      \"pmids\": [\"2145398\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"GABA increases Thr34-phosphorylation of DARPP-32 in striatal and substantia nigra slices through GABA-A receptors (blocked by bicuculline); the mechanism is consistent with GABA reducing calcineurin-mediated dephosphorylation rather than directly activating PKA (cAMP was not elevated).\",\n      \"method\": \"Striatal and substantia nigra slice [32P] phosphorylation assay; GABA-A/B receptor antagonists; pharmacological synergy with forskolin/L-DOPA\",\n      \"journal\": \"Journal of neurochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — pharmacological dissection in intact tissue, mechanistic inference indirect, single lab\",\n      \"pmids\": [\"7931332\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"Mu-opioid receptors (via DAMGO) specifically inhibit D1-stimulated DARPP-32 phosphorylation in striatonigral neurons, while delta-opioid receptors (via DPDPE) specifically inhibit A2A-stimulated DARPP-32 phosphorylation in striatopallidal neurons; kappa-opioid receptors had no effect.\",\n      \"method\": \"Rat striatal slice phosphorylation assay with selective opioid receptor agonists; D1 and A2A receptor pharmacology\",\n      \"journal\": \"The European journal of neuroscience\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — cell-type-specific pharmacological dissection in intact tissue, single lab\",\n      \"pmids\": [\"10336688\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"DARPP-32 co-immunoprecipitates with all five dopamine receptor subtypes (D1–D5) from rat brain cortex and striatum, suggesting direct or indirect physical association in neurons.\",\n      \"method\": \"Co-immunoprecipitation from brain tissue lysates; western blot; immunohistochemistry\",\n      \"journal\": \"Neuroscience research\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single Co-IP from tissue lysate without reciprocal pulldown or functional consequence, single lab\",\n      \"pmids\": [\"19465068\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1992,\n      \"finding\": \"In choroid plexus epithelial cells, DARPP-32 is phosphorylated in response to factors that increase cAMP (forskolin, isoproterenol, VIP) or cGMP (ANP) or activate other pathways (5-HT), but not by dopamine, indicating context-specific regulation of DARPP-32 by non-dopaminergic signals.\",\n      \"method\": \"Phosphorylation state-specific monoclonal antibody; intact choroid plexus cell phosphorylation assay; cAMP/cGMP measurements\",\n      \"journal\": \"The Journal of neuroscience\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — phosphorylation state-specific antibody with pharmacological characterization, novel context established, single lab\",\n      \"pmids\": [\"1494946\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"DARPP-32 (PPP1R1B) is a dual-function signaling hub in dopaminoceptive neurons: when phosphorylated at Thr34 by PKA (activated downstream of D1 receptors/cAMP), it becomes a potent nanomolar inhibitor of protein phosphatase-1; when phosphorylated at Thr75 by Cdk5, it instead inhibits PKA by a competitive mechanism. These two phosphorylation states are modulated by CK2 (Ser102/Ser45), CK1 (Ser137), and multiple phosphatases including calcineurin (dephosphorylates Thr34) and a PR72-containing PP2A complex (dephosphorylates Thr75 in a Ca2+-dependent manner), enabling DARPP-32 to integrate dopamine, glutamate, serotonin, adenosine, opioid, GABA, and other signals into graded control of PP1 and PKA activity. In cancer contexts, DARPP-32 forms physical complexes with EGFR/ERBB3, CXCR4, IGF1R, IKKα, SRp20, and Bcl-2, and activates AKT, STAT3, and NF-κB2 pathways to promote survival, invasion, angiogenesis, and drug resistance.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"PPP1R1B (DARPP-32) is a phosphorylation-state-controlled signaling integrator in dopaminoceptive neurons that converts upstream neuromodulatory inputs into bidirectional control of protein phosphatase-1 (PP-1) and PKA activity [#0, #6]. When phosphorylated on Thr34 by PKA — the terminal step of a dopamine→cAMP→PKA cascade engaged downstream of D1 receptors — it becomes a nanomolar inhibitor of PP-1, an inhibition that requires both the phospho-Thr34 active-site contact and an N-terminal RKKIQF motif (Phe11, Ile9) for a two-site interaction with the phosphatase [#0, #2, #7, #8]. The N-terminal region shares sequence identity with phosphatase inhibitor-1, defining a common structural basis for PP-1 inhibition [#4]. A distinct phosphorylation by Cdk5 at Thr75 instead converts DARPP-32 into a competitive inhibitor of PKA, so the protein operates as a reciprocal molecular switch between the two states [#6]. These states are tuned by additional kinases and phosphatases — CK2 phosphorylates Ser45/Ser102 and accelerates PKA phosphorylation of Thr34 [#5, #37], calcineurin (PP2B) is the principal Thr34 phosphatase [#9, #10], and a Ca2+-sensing PR72/PP2A complex dephosphorylates Thr75 [#18] — allowing DARPP-32 to integrate dopamine, glutamate, GABA, adenosine, opioid, and serotonergic signals into graded phosphatase/kinase control [#9, #14, #17, #38, #39]. In vivo, DARPP-32 is essential for molecular, electrophysiological, and behavioral responses to dopamine and psychoactive drugs, acting through site-specific Thr34 and Thr75 phosphorylation to govern responses to cocaine, antidepressants, and L-DOPA-induced dyskinesia [#11, #15, #19, #20]. Beyond neurons, DARPP-32 and its truncated isoform t-DARPP function in epithelial cancers, where they physically partner with EGFR/ERBB3, IGF1R, CXCR4, and IKKα to activate AKT, STAT3, and NF-κB2 signaling and to promote survival, invasion, angiogenesis, and drug resistance [#26, #27, #28, #30, #31, #36].\",\n  \"teleology\": [\n    {\n      \"year\": 1984,\n      \"claim\": \"Established the core biochemical function: that a neuronal phosphoprotein acts as a phosphorylation-dependent inhibitor of PP-1, defining DARPP-32 as a signaling effector rather than a passive substrate.\",\n      \"evidence\": \"In vitro phosphatase inhibition assay with purified DARPP-32 and PP-1; biochemical purification and hydrodynamic characterization\",\n      \"pmids\": [\"6087160\", \"6319628\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not define the responsible kinase or the phosphorylated residue\", \"No structural model of the DARPP-32/PP-1 contact\"]\n    },\n    {\n      \"year\": 1984,\n      \"claim\": \"Identified the activating kinase and signaling input, linking dopamine to DARPP-32 via a cAMP/PKA cascade and showing PKA (and PKG) phosphorylate a single threonine.\",\n      \"evidence\": \"In vitro PKA/PKG kinase assay with phosphopeptide mapping; intact striatal cell [32P] labeling with dopamine and 8-bromo-cAMP\",\n      \"pmids\": [\"6501303\", \"6319627\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Exact residue identity not yet assigned at sequence level\", \"Phosphatase responsible for reversal unknown\"]\n    },\n    {\n      \"year\": 1986,\n      \"claim\": \"Resolved the molecular basis of inhibition by determining the full sequence, mapping the PKA site to Thr34, and revealing homology to inhibitor-1.\",\n      \"evidence\": \"Edman degradation of bovine DARPP-32 peptides; sequence comparison with inhibitor-1\",\n      \"pmids\": [\"3511054\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not define which N-terminal residues contact PP-1\", \"Other phosphorylation sites and their kinases unknown\"]\n    },\n    {\n      \"year\": 1989,\n      \"claim\": \"Showed multi-site regulation by identifying CK2 phosphorylation at Ser45/Ser102 that primes Thr34 phosphorylation, introducing hierarchical control of inhibitory potency.\",\n      \"evidence\": \"In vitro CK2 kinase assay with phosphopeptide sequencing; intact slice labeling; kinetic analysis; endogenous striatal CK2 characterization\",\n      \"pmids\": [\"2557337\", \"2145398\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Physiological trigger of CK2 activity in neurons not defined\", \"Functional impact of Ser45 vs Ser102 not separated in vivo\"]\n    },\n    {\n      \"year\": 1997,\n      \"claim\": \"Defined the structural determinants of PP-1 inhibition, establishing a two-site mechanism requiring both phospho-Thr34 and an N-terminal RKKIQF motif.\",\n      \"evidence\": \"Synthetic peptide competition and DARPP-32 mutagenesis with in vitro PP-1 inhibition assays\",\n      \"pmids\": [\"9108011\", \"10075680\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No co-crystal structure of the DARPP-32/PP-1 complex\", \"Whether the two sites engage PP-1 simultaneously in cells untested\"]\n    },\n    {\n      \"year\": 1997,\n      \"claim\": \"Demonstrated bidirectional dopaminergic control, with D1 increasing and D2 decreasing Thr34 phosphorylation via a Ca2+/calcineurin pathway, and identified calcineurin as the principal Thr34 phosphatase.\",\n      \"evidence\": \"Striatal slice [32P] assays with D1/D2 pharmacology, calcineurin inhibitors, and Ca2+-free media\",\n      \"pmids\": [\"9334390\", \"10217279\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Spatial coupling of calcineurin to DARPP-32 not resolved\", \"Contribution of PP2A versus calcineurin quantitatively uncertain\"]\n    },\n    {\n      \"year\": 1999,\n      \"claim\": \"Revealed the second, opposing switch state: Cdk5 phosphorylation at Thr75 converts DARPP-32 into a competitive PKA inhibitor, making it a reciprocal kinase/phosphatase integrator.\",\n      \"evidence\": \"In vitro Cdk5 kinase assay, intact brain cell labeling, Cdk5 inhibitor and mutant mice, Ca2+ current electrophysiology\",\n      \"pmids\": [\"10604473\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Phosphatase reversing Thr75 not yet identified at this stage\", \"Crosstalk dynamics between Thr34 and Thr75 states unresolved\"]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"Established physiological necessity in vivo by showing DARPP-32 knockout disrupts dopaminergic molecular, electrophysiological, and behavioral responses.\",\n      \"evidence\": \"Targeted knockout mouse with behavioral, electrophysiological, and biochemical readouts\",\n      \"pmids\": [\"9694658\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not separate Thr34 from Thr75 contributions\", \"Cell-type-specific roles not resolved\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Mapped DARPP-32 downstream effectors and broadened its signaling inputs, linking it to GABA(A), NMDA, AMPA-receptor regulation and to adenosine, serotonergic, and antidepressant pathways through site-specific phosphorylation.\",\n      \"evidence\": \"DARPP-32 knockout mice, slice electrophysiology, phospho-specific immunoblots, and pharmacology across striatal, accumbens, and cortical preparations\",\n      \"pmids\": [\"10805695\", \"12181566\", \"11880651\", \"12068305\", \"15657149\", \"7931332\", \"10336688\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Quantitative integration of competing inputs at single-neuron resolution incomplete\", \"Direct substrate phosphorylation by PP-1/PKA versus indirect effects not always separated\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Identified the Ca2+-sensing Thr75 phosphatase, showing a PR72/PP2A complex with functional EF-hands dephosphorylates Thr75 in response to glutamate-driven Ca2+.\",\n      \"evidence\": \"PR72 overexpression/RNAi, EF-hand mutagenesis, in vitro PP2A assay, and striatal slice phosphorylation with glutamate receptor pharmacology\",\n      \"pmids\": [\"17535922\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Stoichiometry and assembly of the PR72/PP2A/DARPP-32 module unresolved\", \"Whether PR72 directly binds DARPP-32 not shown\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Resolved cell-type-specific regulation, showing psychostimulants and antipsychotics drive Thr34 phosphorylation in opposite striatal neuron populations, and dissected site-specific behavioral roles.\",\n      \"evidence\": \"BAC transgenic and T34A/T75A knock-in mice with FACS-based phospho-analysis and behavioral assays\",\n      \"pmids\": [\"18622401\", \"16123776\", \"17596448\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular basis of divergent D1 versus D2 neuron responses not fully defined\", \"Link from H3/ERK cascade to specific transcriptional programs incomplete\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Extended DARPP-32 function beyond neurons to epithelial and reproductive contexts, showing canonical Thr34/PP-1 signaling controls cell migration and sexual behavior.\",\n      \"evidence\": \"Wnt-5a/Frizzled-3 signaling with siRNA and Cdc42 assays in MCF-7 cells; DDR1-dependent migration with DARPP-32 mutants; antisense and knockout for progesterone-facilitated receptivity\",\n      \"pmids\": [\"19651774\", \"17027969\", \"10669419\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Antimigratory cancer findings rest largely on single-lab cell models\", \"Generality across epithelial cell types not established\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Placed DARPP-32 in a Ca2+/apoptosis feedback module, showing Bcl-2 docks DARPP-32 with calcineurin on the InsP3R to create a negative-feedback loop that limits apoptosis.\",\n      \"evidence\": \"Reciprocal co-immunoprecipitation, Bcl-2/DARPP-32 RNAi, Ca2+ and apoptosis assays\",\n      \"pmids\": [\"24395794\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Co-IP-based complex not validated structurally\", \"Generality beyond the studied cell systems unclear\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Defined oncogenic protein-complex partners through which DARPP-32/t-DARPP activate survival and invasion pathways, including EGFR/ERBB3, IGF1R, CXCR4, IKKα, SRp20, and downstream AKT/STAT3/NF-κB2 signaling.\",\n      \"evidence\": \"Co-immunoprecipitation, proximity ligation, shRNA/siRNA, organoids, knock-in/knockout and xenograft/orthotopic mouse models, and human tumor tissue analysis\",\n      \"pmids\": [\"21741919\", \"31235784\", \"25779598\", \"26119931\", \"23160836\", \"29782621\", \"27590997\", \"32768595\", \"16061638\", \"12124342\", \"19301121\", \"19593441\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Most interactions established by Co-IP in single labs without structural mapping\", \"Whether catalytic phosphatase-inhibitory activity is required for many cancer phenotypes is inconsistent across studies\", \"t-DARPP versus full-length contributions not always separated\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How the competing Thr34 and Thr75 phosphorylation states, their kinases, and their phosphatases are spatially and temporally coordinated at the level of individual synapses or signaling complexes remains unresolved, as does the structural basis of the many cancer-associated receptor complexes.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No structural model of DARPP-32 bound to PP-1 or to cancer receptor partners\", \"Quantitative model integrating all kinase/phosphatase inputs at single-cell resolution lacking\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [0, 6, 7, 8]},\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [0, 7]},\n      {\"term_id\": \"GO:0060089\", \"supporting_discovery_ids\": [2, 6, 9]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [37]},\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [26, 30]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [2, 6, 9]},\n      {\"term_id\": \"R-HSA-112316\", \"supporting_discovery_ids\": [11, 12, 16]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [26, 28, 30, 31]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"PPP1CA\", \"CDK5\", \"CSNK2A1\", \"PPP3CA\", \"EGFR\", \"ERBB3\", \"IGF1R\", \"CXCR4\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"faith_supported":7,"faith_total":7,"faith_pct":100.0}}